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The use of stereotactic body radiation therapy (SBRT) for lung treatments is very popu-
lar in radiotherapy clinics. This is because of its better results compared to the other 
treatments. The development of flattening filter free (FFF) beams has given a new per-
spective to this treatment. In this thesis, the commissioning of SBRT FFF beam for cen-
tral lung treatment was aimed.  
 
Two spherical volumes of diameter 3 cm (PTV 3) and 6 cm (PTV 6) representing the 
planning target volumes were created within the central lung area in Alderson phantom. 
The dose plan for the treatment was done for 6 MV FFF photon beam using stereotactic 
radiotherapy (SRT) volume modulated arc therapy (VMAT) and dose fractions of 4 Gy, 
7.5 Gy, 11 Gy and 18 Gy. Dose distribution calculations were performed in Eclipse 
treatment planning system (Varian Medical Systems, Palo Alto, CA). Radiation Ther-
apy Oncology Group (RTOG) protocol was utilized to obtain the required dose confor-
mity within the target. Dose plan verification was done by ionization chamber matrix 
detector (in two different setups: combined with the cubic solid water phantom and 
mounted in the gantry) and radiochromic film inserted within the cubic solid water 
phantom. Irradiation was done with Varian TrueBeam STx linear accelerator (Varian 
Medical Systems, Palo Alto, CA).  
 
Results of dose conformity were checked using dose-volume histograms (DVH) and 
were in accordance with the RTOG protocol. Moreover, measured and calculated dose 
distribution data were compared using gamma analysis with the acceptance criteria of   
3 %, 3 mm. According to the suggested criteria (less than 5 %) of technical reports se-
ries (TRS) 398, the general average values of the disagreement between measured and 
calculated data obtained from the ion chamber matrix detector for PTV 6 were within 
the required limits, 4.2 % for both of the detector setups. However, this was not the case 
for PTV 3 because the general average values were 6.2 % and 6.5 % for each of the de-
tector setups. Main reasons for these unacceptable results were mostly due to the small 
field sizes and poor resolution of the matrix detector. Film measurements showed very 
satisfactory results regarding the shape of the measured dose profile compared to the 
calculated one. The only problem with film results was the unacceptable absolute dose 
difference between these two dose profiles, approximately 10 %, which most likely was 
due to inaccuracies from film calibration or post processing. 
 
Based on those results, it was concluded that the commissioning of the 6 MV FFF pho-
ton beam for SBRT lung treatment was partly successful. Before its clinical application, 
further studies are needed related to the mentioned dosimetric uncertainties.  
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1. INTRODUCTION 
External radiotherapy is the most common treatment procedure used in oncology. It 
uses one or more external photon beams to treat the tumor inside the patient from out-
side the patient’s body. Its aim is the tumor necrosis by delivering a high dose of radia-
tion to the malignant tissue site and sparing the surrounding healthy tissues as much as 
possible. In other cases it is also used for palliative purposes rather than curative ones. 
[1.] Today there are many techniques utilized to deliver the photon beam to the patient 
with the main ones being three-dimensional conformal radiotherapy (3DCRT) and in-
tensity modulated radiotherapy (IMRT) and volume modulated arc therapy (VMAT); all 
very useful for stereotactic body radiotherapy (SBRT) treatments. SBRT, which is in the 
focus of this work, differs from other treatments because of its higher accuracy and the 
use of high radiation doses in only few fractions. Its implementation started about 20 
years ago and with the further development of computing technology it became a more 
common technique in radiotherapy [2]. It is used for many tumor sites but most com-
monly for lung treatments [3].  
The development of flattening filter free (FFF) beam is thought to give further ad-
vantages to SBRT. The main benefit offered from FFF beam is the possibility of using 
much higher dose rates and therefore a shorter delivery time. Reducing the delivery 
time would keep the patient on the treatment couch for a shorter period. Thus, giving 
more comfort to the patient and decreasing the chances for inaccuracies coming from 
any patient movement. [4.] These are critical elements in SBRT because of the usage of 
high fraction doses and of small margins for planned target volume (PTV), thus requir-
ing very high preciseness. Keeping in mind such benefits, in this thesis work, the com-
missioning of SBRT for 6 MV FFF photon beam was evaluated.  
This thesis is organized in seven main chapters. The first one is the introduction, 
which gives a brief idea of what the thesis will be about. The second chapter describes 
the theoretical background relevant to the thesis work and the aim of this work. The 
third one is concentrated in the details of the materials and methods used to achieve 
such aims. The following chapter, fourth one, presents the results obtained during the 
work. The fifth chapter, discussion, covers the interpretation of the results obtained in 
the previous chapter. The sixth chapter gives a brief summary of the work and con-
cludes in what extent the work aims presented earlier was achieved. The final chapter, 
references, lists all the references used throughout the thesis. 
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2. THEORETICAL BACKGROUND  
2.1. Treatment of cancer 
World Health Organization (WHO) defines cancer as the rapid creation of abnormal 
cells growing beyond their usual boundaries and affecting any part of the body as well 
as extending to other parts. Other terms referring to it in the medical society are malig-
nant tumors and neoplasm. According to a study in 2008, cancer was found to be the 
leading cause of deaths worldwide with 7.6 million or 13 % of the total mortalities. The 
most common sites where cancer is found are lungs, prostate, stomach, liver, breast, 
cervix, etcetera; lungs being the most common one (1.37 million). By 2030, it is esti-
mated that cancer deaths will increase to about 13.1 million. [5.] 
Cancer can be reduced or controlled mainly by early detection and adequate treat-
ment programs also known as cancer therapy. Cancer therapy aims to stop further pro-
gress of the tumour and its removal. The therapy includes four different methods which 
can be applied alone or in combination. These are: surgery, for the physical removal of 
the tumor mass; chemotherapy, a drug treatment for halting tumor’s progress and reduc-
ing it; immunotherapy which uses body’s immune system to change the immune re-
sponse; and radiotherapy which uses the ionizing radiation for treatment. Radiotherapy 
or radiation oncology, which is in the scope of this work, has been a treatment option to 
various cancers for more than 60 years. [1.]  
Radiotherapy, also known as radiation therapy, is the use of high energy X-rays to 
treat different tumors. Its aim is to diminish the tumor by delivering a high dose of radi-
ation to the tumor site and expose as small as possible dose to the healthy tissues sur-
rounding the target or to the ones in the beam’s way. It is also used for palliative pur-
poses rather than curing ones. It can be given from inside the body through sealed radi-
oactive sources placed within the tumor volume, known as brachytherapy or from out-
side via external radiotherapy; the latter being in the focus of this thesis. External beam 
radiotherapy is the most common treatment method used in oncology. The radiation 
source is at a certain distance from the patient and uses an external beam to treat the 
tumor inside the patient. [1.] In most of the cases, this mode uses photon beam, however 
in less cases electron beams and even rarer proton or neutron beams (the last two are not 
yet well established in radiotherapy). The scope of this thesis covers only the photon 
beam and the other methods will not be discussed any further.  
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Photon beam is produced in two ways, gamma rays originating from radioactive nu-
clei and x-rays originating from the interaction of the accelerated electrons with the     
X-ray target installed in the machine’s head. In the second case, the produced photons 
are due to the interaction of the accelerated electrons with the target atoms. Most of the 
kinetic energy is transferred into heat and a small part of it is used to produce the photon 
beam which consists of bremsstrahlung photons and characteristic ones. Based on the 
kinetic energy of the electrons, the photon beam can be produced either within an X-ray 
tube or in a linac. The photon beam produced from electrons with kinetic energy rang-
ing from 10 to 100 keV are called superficial X-rays, the ones from 100 keV to 500 keV 
are called orthovoltage X-rays, and the ones produced with more than 1 MeV energy are 
classified as megavoltage X-rays. The first two groups are produced within the X-ray 
tube and the third one is generated by using linear accelerator. [6.]  
A major element accompanying radiotherapy planning process is the imaging sys-
tem which is most usually based on the computed tomography (CT). Diagnostic proper-
ty of CT images is widely used in external beam radiotherapy for defining the target(s) 
and other structures relevant to the treatment. The images are geometrically accurate 
and provide electron density of the organs, needed for the dose calculations. However, 
its main pitfall is poor soft tissue contrast and it cannot accurately identify all the tissues 
and the target(s), due to different technical reasons. Therefore, other modality such as 
magnetic-resonance-imaging (MRI), which offers a very good soft tissue contrast, is 
used in combination (image fusion) with the CT to complement for the missing data. It 
should be in combination with CT because MRI cannot be used directly in the planning 
process due to the lack of electron density information. This is practically useful in the 
cases of head and neck, and brain tumors. Other modalities, used less frequently, are 
positron emission tomography (PET), single photon emission computed tomography 
(SPECT) and ultrasound. [1; 7.]  
2.2. Medical Linear accelerator (linac) 
2.2.1. Brief history of linac 
Megavoltage external beam radiotherapy dates from 1937. It was the time when radio-
therapy was in the transition process from being palliative to being a curative option for 
the tumor. The idea of linac was introduced as early as in 1928 from Ising, a Swedish 
physicist, who published “On a new principle for the production of higher voltages”. 
However, due to the technological deprivation of that time, the implementation was 
possible only in 1953, when Metropolitan-Vickers Electrical Co Ltd (Mac-Vic) built the 
first linac in the world using 8 MV X-rays with the accelerating waveguide mounted 
vertically (4 m long) and with a stationary gantry.  
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Figure 1. a) 4 MeV linac of 1950s from Mac-Vic, b) 6 MV linac, mid-1960s from Mullard 
Equipment (MEL). Adopted from [8]. 
Figure 1a shows a similar model (to 8 MV one) based on 4 MV photon beam, pro-
duced from Mac-Vic and figure 1b shows 6 MV linac of 1960’s produced from Mullard 
Equipment (MEL). In 1962, Varian Company introduced the first isocentric 6 MV linac 
with a horizontal waveguide. As one can imagine, the machines had their own pitfalls 
and safety issues, mainly because it was new and not-well established technology. [8.] 
Starting from the 1970s the linac had established itself; many more were produced 
which were also more stable and reliable compared to their predecessors. Since then, no 
other radical changes in the concept of clinical linac took place. Throughout the time the 
system was further enhanced and developed with additional and more advanced features 
leading to today’s modern linacs. Due to different accidents, special attention has been 
paid in developing and improving the safety aspects in every step of the machine’s op-
eration. It is worth noticing that the technology has been neither stable nor user-friendly 
until 1980s-1990s when the major technological improvements (for example faster and 
more reliable computers) took place. Due to the rapid development of technology,    
today’s machines, although use the same principle as the earlier ones, are far more ad-
vanced. They support various treatment modes, IMRT and VMAT with included X-ray 
tube together with megavoltage portal imaging device for imaging purposes. Due to 
these developments SBRT performance has significantly progressed. Needless to men-
tion that safety of dose delivery and operation has progressed drastically. [8.]  
The future of linac will be on the further consolidation and development of IMRT 
and especially of IGRT. An example of that would be the idea proposed in 2004 for the 
full integration of linac with MRI scanning machine [9]. Moreover, the possibility to 
combine external beam radiotherapy with other ones (for example chemotherapy) for 
better results is under investigation as well [1].   
a) 
b) 
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2.2.2. Modern linac 
Clinical linacs are cyclic accelerators that accelerate electrons in a straight trajectory 
with kinetic energy from 4 to 25 MeV within a vacuum structure called accelerating 
waveguide. Today, different types of linacs exist, depending on the energy they use and 
their generated beam. Modern linacs are able to produce photon energies of 6 and 18 
MV and electron energies ranging from 6 to 22 MeV and Varian TrueBeam STx (Vari-
an Medical Systems, Palo Alto, CA) used in this paper is one of them.  
The general structure of a medical linac is classified into five key components: 
treatment head (gantry), gantry support, modulator cabinet, patient support system and 
control console, with the most important one being the gantry. On the other hand, the 
beam is formed with the help of the following elements: injection system, radio fre-
quency (RF) power generator, accelerating waveguide, auxiliary system, beam transport 
system, beam collimation and monitoring system (ionization chambers). Figure 2 shows 
a general schematic diagram of such linac. Depending on the producer, there are varia-
tions between machines according to the type of produced beam and its energy. [6.] 
 
Figure 2. Main components composing medical linac. Adopted from [6]. 
Gantry mainly consists of retractable X-ray targets, flattening filters, primary and 
adjustable collimators, dual ionization chambers and multi leaf collimators (MLCs), as 
illustrated in figure 2. The target for photon beams is used in combination with the flat-
tening filter which is mounted in a rotating carousel. Beam collimation is done via the 
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collimators, which are used for shaping the beam to the desired size. MLCs are optional 
in the linacs working with only three-dimensional radiotherapy (3DRT) but they are 
always present in the linacs that support IMRT modalities. They are used to shape the 
beam in the desired form and size. Usually there are 120 leafs, each of them accompa-
nied with computer controlled motors. Ionization chambers are used for monitoring the 
photon beam output expressed in terms of monitor unit (MU). They are usually adjusted 
such that 100 MU corresponds to 1 Gy dose measured in water phantom, at the depth of 
dose at the central axis (CAX) for a field of 10x10 cm
2
 and source-to-surface distance 
(SSD)=100 cm. Other beam parameters controlled from this chamber are the beam’s 
flatness, energy and symmetry. The two chambers work independently of each other so 
if one of them fails the other one still works until the treatment is completed. [10.] 
RF power generator accelerates the electrons to the desired kinetic energy within 
the accelerating waveguide by using microwave radiation. It is referred as microwave 
power source in figure 2. Injection system is the component which produces the elec-
trons and is called the electron gun. The basic injection system contains a filament cath-
ode and punctured grounded anode. Accelerating waveguide is a vacuumed or gas filled 
metallic structure used for electron acceleration. Its length depends on the kinetic ener-
gy of the accelerated electrons and varies from 30 cm to 150 cm for kinetic energies 
varying from 4 MeV to 25 MeV, respectively. Auxiliary system consists of many factors 
which regulate the work of the linac, although not directly involved in electron accelera-
tion. The key factors are water cooling system, shielding against leakage and vacuum 
pumping system. Electron beam transport transports the electrons from the accelerating 
waveguide to the X-ray target (high atomic number (Z) material), usually tungsten, or 
exit window via evacuated drift tubes and bending magnets. The bending angle depends 
on the structure of the machine and it can be of 90
o
, 270
o
 or 112.5
o
. [6.] 
Keeping in mind the major components of the linac just described here, one can eas-
ily understand the production of the clinical photon beam. In few words, the electrons 
are produced from the heated filament in the electron gun, serving as a cathode. These 
electrons are then transferred to the accelerating waveguide where they are accelerated 
to the desired kinetic energy. Next, the accelerated electrons are transferred to the beam 
transport system where the beam bending occurs. Through the bending process, the 
electron wave is directed toward the X-ray target which serves as anode. From the inter-
action of the two, the clinical photon beam, named also as X-rays, is produced (in the 
CAX direction). Most of the kinetic energy of the colliding electrons with the target is 
transferred into heat (the reason for the cooling system) and a small part of it serves for 
the photon production. From the interaction of the electrons with the target, two kinds of 
X-rays are produced: characteristic ones and bremsstrahlung ones. In brief, the first kind 
is generated as a result of Coulomb interaction between the incident electrons and the 
atomic orbital electrons of the target. Meanwhile the second kind is produced from the 
Coulomb interaction between the accelerated electrons and the nuclei of the target.    
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The ratio between these two types of X-rays is dependent on the kinetic energy of the 
electrons and of the target material. In the linac case, the bremsstrahlung X-rays domi-
nate the produced beam. Until it reaches the patient, the beam goes through some pro-
cessing. It is firstly shaped by the collimators, then flattened via the flattening filter and 
afterwards is shaped to the desired parameters via the jaw system and MLC system. [6.]  
2.3. Clinical Radiotherapy 
Since its implementation about 60 years ago, external radiotherapy treatment has gone 
through many developments [2]. There has been several treatment methods used during 
the time, depending on the technology of the day. However, here only the last few of 
them will be discussed: 3DCRT, IMRT, and VMAT which can be all used for SBRT 
treatments. 
Today, radiotherapy treatment is already headed toward the intensity modulated 
beam treatment which is the common feature of the last two methods. Before explaining 
each of them, it will be useful to explain few clinical structure definitions.  
2.3.1. Clinical structure definitions 
The aim of radiotherapy is to irradiate the target meanwhile sparing the healthy tissues 
around the target as much as possible. Therefore, external photon beam is carried out by 
using multiple beams at different angles. An important factor of an efficient curative 
treatment is the volume definition of the involved structures within the patient’s body. 
The main volumes defined from the radiation oncologist are the gross tumor volume 
(GTV), clinical target volume (CTV), internal target volume (ITV), planned target vol-
ume (PTV) and organ at risk (OAR). 
GTV is the gross visible location of the tumor, including its extensions. GTV is 
practically defined by using any of the imaging modalities CT, MRI, ultrasound or a 
combination of any of them with each other. Other diagnostic modalities are also used.  
CTV is determined by the oncologist and includes the GTV and other surrounding 
sub-clinical malignant diseases targeted for elimination. In most of the cases it is de-
fined as the GTV with an additional margin (most typically between 0.5 mm and 1 cm) 
around it but in other cases it can be the same volume as GTV.  
ITV is defined as the CTV with an additional internal margin. It predicts organ mo-
tion (for example breathing) leading to variations in CTV’s location and size regarding 
to predefined reference points.  
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PTV is the volume that includes the ITV and usually an additional margin (for ex-
ample of 1 cm) around it. This margin is added to account for geometrical uncertainties 
of treatment delivery, certain uncertainties of the machine and of the patient set-up, with 
the ultimate goal of total target irradiation. However, PTV does not take into considera-
tion dosimetry uncertainties because that is taken care of from the treatment planning 
system (TPS). 
Finally, OAR is defined as any organ that has a low radiation tolerance. In some 
cases, new field arrangements need to be done in the TPS so the OAR is not over-
irradiated. OAR can be any organ that is in the beam’s path, no matter the distance from 
the PTV. [6.] 
 
Figure 3. Schematic presentation of clinical structures. Adopted from [6]. 
In this thesis, PTV and GTV are utilized only, for two main reasons. Firstly, ITV 
and CTV are defined in clinical cases therefore they are not applicable to the simula-
tions performed here and secondly, they are not common structures used in SBRT. 
2.3.2. 3DCRT 
In 3DCRT the treatment is based on 3D anatomical information and the treatment plan-
ning aims to have conformed dose distribution to the target and minimize the dose ex-
posure of healthy tissues. The anatomical information is gathered by using two-
dimensional (2D) image slices, which are then combined to create the 3D visualization. 
Afterwards, the delineation of the structures and targets is done through the segmenta-
tion process. Then, fields and beams necessary for the treatment are designed. The op-
timization problem in this case requires modifying constantly several parameters until 
the desired conformity is achieved. These parameters are the number of fields, their 
aperture, beam weights, their directions and beam modifiers (bolus, compensators, 
wedges). Multiple fields are used because it avoids the use of very high energy beams 
and spreads the dose in larger volume. However, creating more than four fields intro-
duces the problem of the beam modifiers’ production. [11.] 
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Beam shaping blocks were created for each field and were time and labor consum-
ing not only in producing them, but also mounting and holding them during the treat-
ment. This problem was significantly improved with the current development of MLC 
system which is used for beam shaping. To achieve the required optimization, beam 
parameters are selected based on trial-and-error method or experience and modified 
iteratively. This meant that for complicated cases, optimization could be a lengthy pro-
cedure, not to mention that it also depended on the planner’s experience, speed of the 
calculating system and other factors. When the plan is optimized and the dose is calcu-
lated, plan evaluation is performed. The evaluation criteria include the dose distribution 
in the target and the dose delivered in healthy tissues. Isodose curves and surfaces can 
be displayed in any desired plan of the patient on the 3D anatomical image and are used 
to check the dose distribution. Dose-volume histograms (DVH) are used to control the 
dose delivered in each of the structures and target volumes. It gives information on the 
minimum, maximum, average dose distribution and its anatomical distribution. [11.]  
2.3.3. IMRT  
The idea of IMRT has started in 1970’s but its practical implementation began later, in 
1990’s, due to the technological limitations. With the development of the more powerful 
computers and imaging techniques, the importance of IMRT has increased since. [1.] 
IMRT is based on the combination of two elements: inverse treatment planning accom-
panied with computerized optimization and the computer-control of the radiation inten-
sity modulation carried out with MLCs during the treatment.  
Inverse treatment planning  
Inverse planning is one of the main advantages of IMRT over the conventional method. 
The key concept of it is that the person who makes the treatment planning chooses beam 
directions, target dose goals and the dose constraints for the structures surrounding the 
target volume. For example, the user defines the minimum and maximum dose to PTV 
and the maximum dose to the organs at risk. Based on the defined requirements, TPS 
perfoms the optimization process in which it divides the beam into smaller beams, 
called beamlets. Intensity of each beamlet is then modified to create the dose distribu-
tion which maximally fits the required one. If the final dose distribution does not meet 
the requirements, then the optimization process can be repeated by modifying goals and 
constraints of the treatment plan. 
 
Technically speaking, goals and constraints are represented from the planning sys-
tem as a cost function which should be maximized or minimized during the optimiza-
tion process. The cost function is considered as a tradeoff between the goals and con-
straints based on the clinical judgement. Modifying any of the goals or constraints will 
change the cost function, thus the final result. The inverse planning and optimization 
process are considered to be very helpful and advantageous compared to the forward 
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planning. However, they do not always offer the best solution right away. That is why 
the cost function should best characterize the clinical concerns. In addition, the user 
should know how to regulate the cost function so the obtained result is better than the 
previous one. [13.] Figure 4 gives the comparison between the traditional (forward) 
planning with the inverse planning used in IMRT. The dashed lines show the dose target 
conformity which is better in inverse planning than in forward one. 
 
 
Figure 4. a) Traditional/forward planning. A: the setup of the fields conform the target volume 
(in red). B: beam modifiers to reach the required dose distribution. C: the final shape of dose 
distribution. b) Inverse planning: A: setup of field geometry. B: definition of goals and con-
straints for the desired dose. C: modulated fluence resulting from optimization. D: resulting 
dose shape distribution. Adopted from [12]. 
 
IMRT delivery  
The beam modulation in IMRT is fully supported from the MLC system. MLC consists 
of opposing pairs of tungsten leaves which can be controlled independently. Its number 
depends from vendor to vendor. The use of MLC system means also that beam modifi-
ers such as blocks and wedges are no longer used. [13.] Via MLC system variable radia-
tion intensities are generated for each beam. This is done by dividing the beam into 
many beamlets, each with different intensity. The two most common delivery methods 
of IMRT are segmental MLC and dynamic MLC.  
 
a) Forward Planning 
b) Inverse Planning 
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Segmental MLC 
It has been derived from the conformal radiotherapy where for every beam several di-
verse MLC-shaped fields are produced. The beam is kept off during the field shaping 
and turned on when the shaping is completed. Next, the beam is turned off again, leafs 
move to the next position and then beam is turned on. This process is repeated until all 
the modulations are completed. That is why it is also called step-and-shoot technique.  
 
Dynamic MLC 
The only difference with the segmental MLC is that the beam is kept on during the field 
shaping. It is turned off only when the beam is changing the angle. The speed of leafs 
and distance between them is crucial in producing the desired radiation intensities. It 
was observed that it offers a better dose conformity when compared to segmental MLC. 
However, since the beam is all the time on, the dose leakage as well as total body radia-
tion is higher. Dynamic MLC is known also as the sliding window technique. To sum-
marize IMRT, table 1 gives some of the advantages and disadvantages of IMRT. [7.] 
Table 1. Advantages and disadvantages of IMRT. Adopted from [7] 
Advantages Improved 
target       
conformity 
Intentional 
dose inhomo-
geneity is   
possible 
Better normal 
tissue sparing 
Dose    
escalation 
Can     
compensate 
for missing 
tissue 
Disadvantages Target and 
OARs outlin-
ing takes long-
er clinical time 
Needs a broad 
quality assur-
ance program 
Machine 
treatment 
time is longer 
Planning 
time is also 
longer 
Scattered 
and leakage 
radiation is 
higher. 
 
2.3.4. VMAT 
Rotational arc therapy known also as VMAT or intensity modulated arc therapy (IMAT) 
has been proposed in 1995, even earlier than IMRT was implemented. The proposed 
idea was the same as it is today, the MLC modulated beams are delivered as the gantry 
rotates. However, its implementation took place few years later due to the technological 
inferiority of that time. VMAT (the term that will be used from now on) is similar to the 
IMRT with dynamic MLC. The difference here is that IMRT is applied in few certain 
angles, depending on the amount of treatment beams while VMAT is the IMRT applica-
tion for every angle of the rotation arc around the patient. VMAT is considered to be a 
more efficient delivery method compared to IMRT and it is as good as or even superior 
to IMRT plans. However, its main drawback is the optimization process which is time 
consuming due to its demand for high computation power. In this aspect, multicriteria 
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optimization and the engagement of powerful computers have proven to reduce the op-
timizing time significantly. [14.]   
In a recent study conducted for pulmonary SBRT patients with tumors nearby the 
chest wall, VMAT SBRT seemed to have some advantages compared to traditional 
SBRT treatments. The gantry movement at the same time as the MLC modulation of-
fered more optimal treatment planning and dose delivery. Compared to IMRT SBRT 
method, it was noticed that in VMAT there was a considerable volume reduction in re-
ceving the same prescribed dose. Table 2, which displays the average data gathered 
from ten patients included in the study, supports such advantage. [15.]  
Table 2. A comparison of the volume of chest wall, rib volume and lung volume receiving the 
prescribed tumor dose of 30 Gy, for two different SBRT techniques. Data are the average for 10 
patients included in the study. The significant difference between the volumes receiving the 
same dose shows the advantage of VMAT SBRT. Adopted from [15]. 
 
 Chest wall (cm
3
) Rib volume (cm
3
) Lung volume (cm
3
) 
IMRT SBRT 193.9 13 12.4 
VMAT SBRT 47.6 6.3 10.2 
Other advantage of VMAT SBRT compared to noncoplanar IMRT plans for lung 
treatments is the speed of treatment delivery. According to radiation therapy oncology 
group (RTOG) 0915, for the same treatment case, VMAT plan required an average time 
delivery of 6.5 min compared to 23.7 min for IMRT technique. It is a considerable dif-
ference because shorter delivery time leads to smaller risk for target motion and more 
comfortable treatment for the patient. [16.] Table 3 gives a good summary and compari-
son between non-SBRT and SBRT treatments. 
Table 3. Comparisons between the non-SBRT and SBRT treatment methods. Adopted from [2]. 
Characteristics 3D/IMRT SBRT 
Dose fraction 1.8-3 Gy 6-30 Gy 
Number of fractions 10-30 1-5 
Target definition May not have sharp boundary Well defined, GTV=CTV 
Margin Centimetres millimiters 
Primary image modality 
used for treatment planning 
CT 
Multimodality:  
CT/MRI/PET-CT 
Maintenance of high target-
ing accuracy during treatm. 
Moderately enforced Strictly enforced 
Respiratory motion man-
agement 
Moderate Highest 
Radiobiological knowledge Moderately well understood Poorly understood 
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2.3.5. SBRT  
SBRT is a common technique used in radiotherapy for treating mainly early stage pri-
mary and oligometastatic cancers in thoracic cavities, abdomino-pelvic ones as well as 
in (para) spinal areas; the major treatment site being the lungs [2]. Stereotactic treatment 
started in 1992 in Sweden after an extracranial stereotactic frame was developed to be 
used for treating chest and abdomen tumors [9]. Since then, the technique has improved 
further and became more popular after seeing its advantages toward conventional treat-
ments. 
The key features characterizing it are the use of few fractions with very high doses 
used in small target volumes accompanied with small margins and utilizing a very pre-
cise localization of the target (optional is the use of patient fixation frames). Because of 
the high dose/fraction, the biological effects are also high both in non healthy and 
healthy tissues. To minimize the healthy tissue radiation and maximize the target radia-
tion, a great priority is given to dose conformity. Not only is tumor localization very 
precise but also image guidance throughout the treatment is utilized. The precise tumor 
location is guaranteed by applying accurate structure delineation and advanced imaging 
techniques, MRI, 3D CT/four-dimensional (4D) CT, SPECT and PET. Moreover, com-
pared to conventional treatments, in SBRT the number of treatment fields is higher. 
SBRT can be performed either with static fields (3DCRT), IMRT, a combination of the 
two or VMAT technique, depending on the treatment case. Also the beams can be co-
planar or non coplanar, flattened or unflattened. [2.] The selection of these options be-
comes crucial when talking about dose delivery time. Often, long delivery times are 
problematic for patients who cannot stay in one fixed position due to the pains or medi-
cal problems they have. Thus, VMAT SBRT techniques are considered to offer the best 
solution. According to Holt et al. [18], SBRT using IMRT takes about 30 to 45 min as a 
total treatment time (including the patient setup and post-radiation monitoring), mean-
while VMAT SBRT takes no longer than 20 to 25 min for the overall treatment time. 
This advantage makes VMAT technique a more favourable option and that is one rea-
son why it is the chosen one in this thesis. 
In SBRT, the usual daily dose ranges from 8-30 Gy (conventional one ranges be-
tween 1.8-2.5 Gy) and the whole treatment course is expected to last one to two weeks. 
Application of such high dosage is seen to have better effects on the tumor, as it has 
been shown from different radiobiological reports. The complete response of the tumor 
after the SBRT was reported to be about 50 % and that is much better than the 20 % 
response coming from the conventional treatment. This implies that the tumor growth 
disrupts and becomes weak enough for the immune system to reduce it. However the 
dose delivery accuracy has to be very high so as less healthy tissue as possible is ex-
posed to the high dose. That is why the treatment is conducted very carefully and the 
latest technology is applied to assess it. For more detailed information, RTOG 0236 
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protocol describes thoroughly the procedures to be followed for the application of 
SBRT technique and RTOG 0915 describes SBRT application for medically inoperable 
stage I peripheral non-small cell lung cancer (NSCLC). RTOG 0618 gives information 
on the non-small lung medically operable lung tumors using the same doses as in 
RTOG 0236 [17]. 
Patient selection criteria and recommendations 
SBRT is mostly applied for medically inoperable patients (usually old aged) who suffer 
from other medical problems and long treatment times are an issue for them [18]. Pa-
tients with lung cancer chosen for SBRT treatments are squamous cell carcinoma, ade-
nocarcinoma, large cell carcinoma, large cell neuroendocrine, and non-small cell carci-
noma. The tumor is well defined and the maximum cross-sectional diameter reaches up 
to 5 cm. However, the diameter value varies from hospital to hospital and it can get also 
up to 7 cm in few cases. [2.] Another important aspect is the amount of beams applied 
in this treatment which however is not well defined because it depends on the hospital’s 
experience and the case at hand. For example, the treatment of Stage I lung cancer has 
been treated with seven to ten non coplanar beams. According to RTOG 0618 recom-
mendations, patients with operable stage I or II NSCLC are advised to be treated with 
non coplanar, non opposing beams. The recommended amount of beams is not less than 
ten, all with approximately equal weights. If static field SBRT is applied, not less than 
seven non opposing beams are advised. [3.] 
Dose constraints 
From this perspective, a common term used for parallel tissues (for example liver and 
lung) is the critical volume, which is defined as the absolute volume of an organ that 
must be saved in order for it to still function. For example, the crit ical volume of liver is 
one third, meaning that if more than that is removed or damaged, the organ will not per-
form its basic functions. For serial tissues (for example esophagus, nerves and airways) 
the damage is reliant on the maximum dose delivered and even a small damage of the 
organ may result fatal. Therefore, avoiding the serial tissue organs as much as possible 
and keeping in mind the critical volumes are some of the main priorities when applying 
SBRT. [17.] 
Immobilization and motion assessment 
As mentioned earlier, one of the crucial elements of the SBRT treatment is the pa-
tient fixation and motion evaluation. For this reason, various fixating equipments have 
been developed including body frames, vacuum pillows and frames used for local fixa-
tions. It is important that regardless of the chosen method, patient should feel comfort-
able during the treatment and the setup would be clinically efficient. The setup is re-
corded in detail in the patient’s files, so it would be easy to reproduce the setup again 
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for the next treatment. Tumor motion is a delicate aspect to be dealt with, especially in 
SBRT when the treatment dose is very high and margins are very small. Most common 
cases of motion assessment are related to the respiratory ones. [17.] For the manage-
ment of tumor movement various approaches are used, including tumor tracking, gating 
delivery and breath control techniques [16]. Motion assessment can be done also with 
different image modalities, depending on the case. For example, for lung tumors, real-
time fluoroscopy and 4D CT can be used [17]. 
2.4. FF vs. FFF beams 
The principle of a standard linac as explained earlier (in chapter 2.2.2) is to accelerate 
the electrons to kinetic energy from 4 to 25 MeV which hit the X-ray target to produce 
photon radiation. The flattening filter (FF) is located in the gantry of the linac, between 
the primary collimator and the ionization chamber (figure 1) and its purpose is to flatten 
the output dose so it has a uniform distribution at the reference depth. As shown in   
figure 1, it has a conical shape and is usually made of copper, but it can also be made of 
any other high Z material. Beside the beam uniformity, FF also causes the reduction of 
the dose rate and is a major reason for photons scattered from the head. [19.] The re-
moval of FF from the path of X-ray beam would significantly increase the intensity of 
the beam, as the graph of figure 5 illustrates, and that has proven to be benefitial to ex-
ternal radiotherapy. 
The development of new therapy techniques (for example stereotactic radiosur-
gery/radiotherapy (SRS)) and the better use of IMRT hinted that the inhomogeneous 
dose delivery is found to be more useful than it was considered before [19]. SBRT 
treatment has often been prolonged due to the limited dose rate and the necessity for 
using many beams, among others. The dose rate offered from conventional methods 
(adding here the setup time) has resulted in a total treatment time of about one hour for 
NSCLC treatment. This long time posses the risk of tumor displacement during the 
treatment and discomfort to the patient. That is why alternative methods such as flatten-
ing filter free (FFF) beam, which offer faster treatments through higher dose rates, are 
investigated. [4.] Brief advantages and disadvantages of FFF beams are given next. 
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Figure 5. FFF X-ray normalized profile graphed against the flat (conventional) beam profile. 
X-axis gives the distance going further from CAX and Y-axis gives the dose in percentage. Flat-
tened X-ray profile is generated by attenuating the raw beam with a flattening filter. FFF mode 
is achieved by removing the flattening filter from the X-ray beam path. Thus the intensity is 
increased (by nearly 200 %) near the central axis with an un-flat (conical shaped) beam profile, 
shown in pink. Adopted from [20]. 
 
2.4.1. Advantages of FFF beam 
 Flattening filter removal increases the dose rate and dose per pulse, softens the 
beam and reduces the energy variation across the beam, the out of field dose and 
photon head leakage [19].  
 The graph of figure 5 gives one of the main characteristics that distinguish the 
flattened beam profile and the FFF one. The increased dose rate leads to reduced 
treatment time compared to the FF beam, for the same amount of dose. For ex-
ample, prostate and nasopharynx treatments were reduced on time by 43 % [21]. 
Also, the estimated delivery dose rate for FFF was 1400 MU/min which is be-
tween 2 to 4 times higher than the FF beam delivery dose [22]. Another experi-
ment ran in Amsterdam University Medical Center gave evidence about the fur-
ther advantages of the FFF beam in SBRT treatment. The study included twenty 
patients with ten of them having peripheral lung tumors and the other ten with 
vertebral metastases. VMAT was used to generate the treatment plans for unflat-
tened 6 MV beams and the flattened one. Results showed that FFF beam plan’s 
delivery time was 2.5 times shorter than the FF beam. [4.] 
 Based on certain studies, it was noticed that the head scattering reduces to 1.5 %, 
compared to 8 % of the FF beam for the field sizes from 3x3 to 40x40 cm. The 
scattering reduction has a positive impact on lowering the risks of a secondary 
induced cancer for the treated patient. [4.] For these reasons FFF beam treatment 
seems to be beneficial for SBRT and SRS future treatments. 
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2.4.2. Limitations of FFF beam 
Knowing that flattening filter free beam mode is a relatively new technology, there are 
still some uncertainties that need to be clarified before it becomes a full replacement to 
the flattened beam option. Some of the limitations presented from different published 
papers are reflected here. 
 One aspect that needs to be dealt with is to set new technical criteria, standards 
and definitions regarding the FFF beam, similar as they exist for the convention-
al beam. Some of them include the initial acceptance measurements, and the   
periodic quality assurance which can be performed in daily, monthly or even 
yearly bases. [20.] 
 The application of FFF beam requires further development of the today’s MLC 
technology because for many optimized segments in static IMRT the traveling 
time of the leaf is too long and for dynamic and rotational IMRT, the speed of 
the leaf collimators is slower than required [19]. Moreover, the limitation is 
more evident for large treatment fields. When such fields are in use, MLC are 
used to regulate the central high intensity of the beam, for example supplying a 
more uniformed dose within the large PTV. Consequently larger and faster 
MLCs are needed. Providing beam uniformity would also lead to a reduction in 
the initial dose rate, which actually was one of the main advantages of the FFF 
beam. [22.] This means that FFF beam delivery is more efficient in lesions of 
relatively small size [23].  
 More information is needed when it comes to the immediate and long term bio-
logical effects of the very high dose rates on the healthy tissues and the ones   
inside the target volume [20]. In addition, all dosimetric properties and beam 
modeling, beam data acquisition and absolute dosimetry of the beam have to be 
carefully studied especially when it comes to small field applications [22].  
 Lastly, some other uncertainties that need to be clarified are related to the higher 
dose rates and the performance of the radiation detectors, starting from the ion 
chambers to the portal imaging devices [24]. 
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2.5. Treatment Planning System 
2.5.1. Principles of radiotherapy treatment planning system 
Generally speaking TPS is a system where the radiation treatment planning is done. The 
plan is based on the acquired images of the patient and the operator tries to optimize the 
dose distribution in the target volume as desired from the oncologist. Treatment plan-
ning systems have been developed a long time ago and the first ones were analog, dedi-
cated to calculate the 2D dose distribution. The first such computer named “Wheatley 
Integrator” was reported in New York and was capable of working with irregular fields. 
The isodose distribution was represented with a matrix of numbers stored in punch 
cards. A similar method was used also in brachytherapy. Then, in 1960’s a digital com-
puter (yet incomparable to the today’s ones) was developed to produce several depth 
dose tables and isodose charts. As technology started to develop even more, TPS devel-
oped into a more robust and user friendly tool. Every time technology advanced, TPS 
became faster and more accurate with better graphic displays.  
As for the inverse planning, although it has been thought and studied since 1960’s, it 
became clinically useful only recently with the development of faster and more power-
ful computers. Today, TPS has improved sufficiently to plan in 3D, use images acquired 
from different imaging modalities, perform virtual simulation and provide DVH data. It 
also offers plan optimizations considering biological aspects and developed many other 
tools to make the treatment planning as accurate and user friendly as possible. [12.]  
Eclipse TPS version 10.0 (Varian Medical Systems, Palo Alto, CA) provided from 
Varian is intended to support features that help in making an efficient treatment by 
providing beam modeling (treatment field(s) setup), patient modeling (by utilizing 3D 
imaging, characterization of the anatomical structures and target volume) and calcula-
tion algorithm. In addition, virtual simulation, dose calculation and plan evaluation is 
performed in order to support those functions. TPS consists of several important appli-
cations which are used in different stages of treatment planning construction.  
Contouring application is used to prepare and modify the patient’s images accord-
ing to the user’s requirements before the beam delivery is performed. Here the desired 
images can be selected, edited, deleted, imported, exported or modified. The application 
supports images coming from different imaging sources like CT or MRI. Images are 2D 
slices and their reconstruction forms the 3D model of the patient. Moreover, image pro-
cessing is also provided here, mainly image enhancement (for example filtering). Rele-
vant anatomical structures and targets can be outlined by using automatic or manual 
image segmentation. It is a crucial application because it is responsible for defining the 
anatomical structures relevant to the treatment; the better it is used, the more curative 
the treatment is. [1.] Another feature of Eclipse TPS is the image registration which is 
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an optional tool for the user. Image registration can be completed via automatic registra-
tion, manual translation, rotation and via registration points.  
External Beam Planning is the application where treatment plans for target irradia-
tion are constructed. It works based on the images prepared in the previous application 
and they are shown in three 2D different planes: frontal, sagittal and transversal as 
shown in figure 6; additionally it offers a fourth solid 3D image or beam’s eye view 
(BEV) image, which is a 2D image reconstructed from beam direction illustrating pa-
tient’s anatomy and beam modifiers. The purpose is to deliver the required dose to the 
target according to the user’s specifications. The user can create and employ as many 
treatment fields as required and can characterize them individually. Field accessories 
can also be chosen here, including MLC, bolus, wedges and other beam modifiers. After 
the fields are planned, the dose calculation can be performed. Depending on the treat-
ment method, optimization can be also performed prior to the dose calculation. 
 
Figure 6. a) transversal, b) sagittal and c) frontal view of the PTV with diameter 3 cm in the 
central lung area. The red contour represents the PTV and the gray area inside PTV represents 
the GTV with diameter 2 cm. 
Another important application in the Eclipse is the plan evaluation. As the name 
hints, it is used to analyze a plan or analyze and compare multiple plans in order to   
select the most appropriate one. When the dose calculation is completed, the dose     
distribution can be visualized in 2D either with isodose lines or color wash or in 3D by 
applying isodose surfaces or dose cloud modes. Beside the visual assessment, a numeri-
cal evaluation can also be employed by the use of DVH and dose statistics (max, min, 
average dose). Similar to external beam planning application, the current application 
also offers specific tools concerning the amount of MU used in each field, field weights, 
normalization options, dose at reference points and absolute dose. What makes the plan 
evaluation application special is the ability it offers to compare different plans side by 
side, add or subtract them even though they may be of different nature (for example 
brachytherapy plan and external beam plan). [12.] 
2.5.2. Analytical Anisotropic Algorithm 
A crucial element of the TPS is the dose calculation algorithm which is created to pre-
dict as accurately as possible the dose distribution within the patient. It is a very com-
plex algorithm because of the complex interaction of the radiation beam with the pa-
tient’s body. The algorithm is intended to consider the different tissue densities which 
a) b) c) 
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get in the beam’s way and other parameters related to both the patient and the machine. 
Combining this complexity with the fast calculation demands presents limitations to the 
algorithm itself. Nevertheless, for common clinical conditions, it delivers very good 
results for reasonable time duration. Important to mention is that the accuracy of the 
algorithm at some extent depends on the user’s input. Before it does any calculation, 
every algorithm needs some input data which is used as reference points for the dose 
computations. Therefore, the accuracy depends on the scale of the uncertainties of the 
physical measurements, the type and size of the used detectors and many other factors. 
The main difference between different TPSs is the dose calculation algorithm that each 
of them uses and for commercial reasons, these algorithms remain disclosed. [25.] The 
one used in Eclipse TPS is called analytical anisotropic algorithm (AAA) version 
10.0.28 (Varian Medical Systems, Palo Alto, CA).  
AAA algorithm used in Eclipse treatment planning system is a fast and accurate al-
gorithm that calculates the dose in both homogeneous and non homogeneous tissues for 
all types of photon external beam treatments. The algorithm is based on a 3D pencil 
beam convolution-superposition algorithm which models the primary photons, scattered 
extra-focal photons and electron scattering independently. The analytical convolution 
employed by the algorithm reduces the calculation time considerably. AAA algorithm 
configuration is mainly based on Monte-Carlo stimulations and beam modifiers (for 
example MLCs, wedges, compensators and others) are included in the final dose calcu-
lations. AAA algorithm is composed of two main elements, configuration algorithm and 
actual dose calculation algorithm. [26.] 
Configuration Algorithm 
This module approximates the phase space of the linac’s photon beam which contains 
information about the particle type of the beam, fluence and energy. The approximation 
is done with the help of a multiple source model consisting of the primary photon 
source, extra focal photon source (second source) and the electron contamination model 
source which are shortly explained next. The aim of this module is to process the meas-
ured data of the beam and verify them for any measurement imprecision; if positive, 
they are corrected. [27.]  
The primary photon source represents the photon spectra which describes the inter-
action of the accelerated electrons with the X-ray target producing the bremsstrahlung 
photons. The spectra are modeled from the Monte Carlo methods and are tested for 
various targets within the Varian linacs. Another task of this source is to model the 
beam hardening effect from the flattening filter which tells that the photon’s beam mean 
energy declines as the distance from CAX increases. [27.] 
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Extra focal photon source, also known as the second source, models the photon pro-
duced outside the target, within the accelerator’s head. The effect of secondary photons 
is higher outside the beam defined from the primary source than inside. This is ex-
plained from the fact that the secondary source lies lower than the primary one thus the 
deviation is higher. However, this effect does not exist in the FFF beams because the 
flattening filter is the main source of deviation and removing it eliminates the prob-
lem.[26.] 
Electron contamination source models the dose in the buildup region not taken into 
account from the primary and secondary sources. Its second function is to describe the 
photons coming from electron interactions, classified as contamination. In the photon 
beam, the contamination depends significantly on beam energy and field size. Electron 
contamination in the primary photon beam results from the flattening filter, collimator 
jaws and air, when no beam modifiers are used. In case modifiers are used, they become 
secondary electron contamination sources. Electron contamination is given by a depth-
dependent curve which shows electron contamination dose versus depth. [26.] 
Photon dose calculation module 
For the volumetric dose distribution calculation, the body is modelled as a grid of indi-
vidual voxels where the voxel size is determined from the selected grid size (minimum 
1 mm). The geometry of the voxel matrix is aligned with the fan beam lines and based 
on the patient’s CT images, electron density is calculated for every voxel [27]. The 
beam is split into beamlets which are along with the body’s voxels. For each beamlet, 
dose calculation module calculates the dose. The superposition of the individual doses 
results into the final dose calculation. All AAA measurements and calculations are done 
in a water equivalent medium and then adjusted to the tissue density of the patient. [26.]  
Photon dose calculation is done by considering the photon beam attenuation and 
photon scattering for each beamlet. It is expressed as the energy deposition density 
function         and considers also the tissue heterogeneity; photon scattering is ex-
pressed as a scatter kernel          . First, the dose convolution is calculated in terms 
of energy and then by using the scaled-water estimation, it is converted into dose. The 
energy at a certain beamlet is calculated by using equation 1. 
                                   (1) 
where      stands for the photon energy at beamlet β. While (        gives the rela-
tive position of (x, y, z) with regard to the origin of the beamlet coordinate system. 
Symbol   is the homogeneous photon flux in the beamlet’s cross-section. In more de-
tails,        is given in equation 2 where z is the depth of the energy deposition, ρ is the 
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electron density and z’ is used instead of z in order to consider the non homogeneities 
between the calculation point and the entry point of the beam.   
               
        
      
     (2) 
Tissue heterogeneity is accounted by utilizing the radiological depth Z’ given in 
equation 3:  
    
        
      
 
 
       (3) 
A similar method followed for the beamlet’s photon dose calculation is used to   
calculate the primary and secondary photon sources. However, spectral composition, 
focal spot size and position are excluded from the calculations. 
Superposition and dose conversion 
The total absorbed energy at any voxel in the patient, expressed as            is calcu-
lated by adding the individual energies coming from primary photon source, secondary 
photon source and electron contamination source for each beamlet, β, which are repre-
sented respectively by the first, second and third elements within the parantheses of the 
right side of equation4.  
                                                                    (4) 
Finally, to obtain the dose, the total energy calculated from equation 4 is converted 
into dose by assuming that different non homogeneities can be modelled as scaled    
water. The dose resulting from this conversion is given in equation 5.  
                     
      
        
    (5) 
Coefficient c is used for the unit conversion from J/m
3
 to Gy. 
Monitor Unit calculation 
In radiotherapy it is very important to check the correct delivery of the radiation to the 
patient before and during the treatment. One of the main components of this control is 
the estimation of the MU. MUs are estimated independently and provide information on 
the amount of radiation delivered to the patient or the linac’s output. Back in time it 
used to be manually calculated and to be sure, two independent persons did the calcula-
tions. Because the used methods were almost the same, the agreement between the re-
sults was not difficult. However, the development of advanced computers, 3D imaging 
and modern TPSs has changed the way MUs are calculated. Today’s algorithm applied 
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for the MU calculation are based on 3D patient modeling and non homogeneous tissue 
density, thus making it more accurate, very complex and making the manual calculation 
almost impossible. [28.] Monitor unit calculation depends on many factors. The contri-
bution of prescribed dose, field weight, plan as well as field normalization and the nor-
malization factor itself are considered when calculating the final MU. For AAA, the 
normalization factor is the value of MU equivalent to 1 Gy to 100 % of the current field. 
Therefore, the MU expressed as MUnorm is calculated at the normalized point from equa-
tion 6.  
                  
       
      
    
    
         
  
 
       
  (6) 
Where CBSF (x,y) is the collimator backscatter factor for an open field. It is calculated 
by using the output factor results obtained during the beam data configuration. 
        is the value of reference dose in MU at calibration depth. It is given from the 
user. 
       is the value of reference dose [Gy] at calibration depth, also given from the user.  
     is the calculated dose from AAA at the calibration depth for the reference condi-
tions. It is considered also as the absolute dose scaling factor value. 
           is the dose calculated at the field normalization point. 
         is wedge correction factor with the collimator jaw settings. In this thesis, no 
wedges are used, therefore its value = 1.  
For more detailed information on the calculation techniques used from AAA, one can 
refer to the Eclipse Algorithms Reference Guide provided from Varian Medical Sys-
tems [26].  
2.5.3. Optimization of dose distribution 
Before the calculations are completed the plans need to be optimized in order to meet 
the dose-volume objectives. For this reason, four optimization algorithms are used from 
the AAA algorithm: dose volume optimizer (DVO), plan geometry optimization algo-
rithm (PGO), progressive resolution optimizer (PRO) and multi-resolution dose calcula-
tion (MRDC).  
DVO, used for IMRT treatments, optimizes the field shape and intensity by chang-
ing continuously the dose distribution within the target. Since it works based on itera-
tive method, the initial (fluence) guess is zero. Then, the fluence is iteratively optimized 
from the algorithm and the dose of the new fluence is calculated. 
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PGO is supported from the DVO algorithm and it utilizes the same objectives. Its 
aim is to automatically choose the optimal beam angles which help to speed up the 
achievement of defined dose-volume goals set from the user. Although they use the 
same DVH-based objectives, PGO runs before the DVO.   
PRO creates the VMAT (named by Varian as RapidArc ®) plans according to the 
dose-volume requirements and other objectives presented from the user. RapidArc 
mode uses dynamic MLCs (DMLC) with their position and MU/degree defined with 
respect to the gantry angle. Moreover, to reach the predefined dose-volume objectives, 
the dose rate and gantry rotation speed are changed during the dose delivery.  
Dose modelling is done by dividing the field into equal small segments and for each 
of them the dose calculation is performed. In the dose calculation there are several   
parameters taken into account, the dose fluence of the apertures, leaf motion and angle 
resolution. Before the optimization process starts, the collimator leafs are conformed to 
the target and dose rates are the same for each segment of the field. At the start of the 
process, the larger adjustments are done to leaf sequencing and as the process continues, 
the adjustments get smaller. As the optimization continues, the dose calculation accu-
racy and dose distribution improve. Finally, the PRO algorithm during the optimization 
also takes into account the non homogeneity correction and air cavity correction factors. 
Dose-Volume objectives 
The objectives for the desired dose-volume are given in two kinds, upper objective and 
lower objective. Upper objective gives the maximum radiation allowed to be given to a 
defined volume of a structure. Lower objective determines the minimum desired dose to 
be given to a certain volume of the chosen structure. In both cases, the desired dose and 
respective volumes are given from the user.  
Normal Tissue Objective (NTO) 
It is used to prevent the hotspots (very high dose regions) in the healthy tissues outside 
the PTV and apply a sharp dose gradient outside the PTV. This parameter is defined 
from four different factors, the distance from the PTV border (      ), start dose (  ), 
end dose (  ) and fall-off factor (k). The first factor, (      ), defines the area where 
NTO value is constant, expressed in cm. The second and third factor, (  ) and (  ), de-
cide the relative dose in % of the NTO at the PTV border and furthest from the PTV 
border, respectively. Lastly, the fall-off factor defines the sharpness of the NTO curve. 
The function of the NTO is computed from equation 7.  
      
   
                   
                      
           
   (7) 
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To control the significance of NTO compared to other objectives, the priority factor 
is used. The higher this factor, the higher the importance of the optimization objective; 
value 0 means that the objective is not taken into consideration from the optimization 
process. [2.] 
2.6. Aims of the thesis 
The purpose of this thesis is to achieve the commissioning of the 6 MV FFF photon 
beam for SBRT lung treatments. This is done by comparing the TPS-calculated dose 
distributions with the measured ones for two different target volumes for four different 
fraction sizes. SBRT was delivered using VMAT technique. The comparison is done 
with gamma analysis and consulting technical reports series (TRS) 398 protocol.  
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3. MATERIALS AND METHODS 
All the calculations and measurements were performed at the department of radiother-
apy at Tampere University Hospital (TAYS). Prior to any calculation, the phantom was 
scanned using Toshiba Aquilion LB X-ray CT (Toshiba Medical Systems Corporation, 
Tokyo, Japan) machine at 120 kVp using slice thicknees of 3 mm and field of view 
52x52 cm (reconstructed image). The phantom used for the calculations was Alderson 
female ART phantom. It was constructed in horizontal slices of 2.5 cm thickness. 
Within the phantom there were materials that had equivalent densities to the bone, soft 
and lung tissues, respectively. Lungs, which were the focus of this work, were          
constructed with syntactic foam with specific gravity of 0.3 g/cc. After the scanning, 
images were electronically transferred using digital imaging and communications in 
medicine (DICOM) standard and saved in the treatment planning system software.  
3.1. Target contouring  
On the acquired CT images two separate spherical GTVs with diameter 2 and 5 cm and 
with electron density values equal to zero Hounsfield unit (HU) were created. HU val-
ues were calibrated to electron density using RMI-phantom (Gammex, Middleton, WI). 
Usually, from the department’s experience, the range of HU values for GTV was      
between -30 to 30 HU, therefore the average was picked. Using the margins of 0.5 cm 
for GTV, two PTVs with diameter 3 cm and 6 cm were created in the central right lung 
area as illustrated in figure 6 and 7, correspondingly. These values were chosen as such 
because these are the typical minimum and maximum target volume sizes in the       
department. From now on PTV of diameter 3 cm and PTV of diameter 6 cm will be 
referred to as PTV 3 and PTV 6, accordingly. For a better comparison, all the created 
structures were isocentric. Then, segmentation process of the structures was implement-
ed with the segmented organs being the lungs and the body (figure 6 and 7).   
 
Figure 7. a) transversal, b) sagittal and c) frontal view of the PTV with diameter 6 cm (PTV 6) 
in the central lung area. The red contour represents the PTV and the gray area within the PTV  
represents the GTV with diameter 5 cm. 
a) b) c) 
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3.2. Dose planning 
As soon as the targets were created and structures were delineated, the calculation pro-
cess in the TPS was started. Eight VMAT plans (with the isocenter at the center of 
PTV) were generated in Eclipse TPS. The machine was set to operate on SRS VMAT 
mode, using a single beam for the RapidArc technique consisting of 1 coplanar partial 
arc with control point (CP) spacing of two degrees. When choosing the direction of the 
SBRT beam, one should take into account several parameters such as machine limita-
tions, shorter beam path and most importantly avoiding the organs at risk as much as 
possible. The direction factor becomes less important when multiple directions are used 
[2]. Therefore, to have a more realistic situation, the chosen direction of the beam was 
from the right side of the lung only, so the left lung is spared from unnecessary dosage. 
In all cases the arc started at 181 degrees and terminated at 45 degrees in the clockwise 
direction; to avoid the MLC tongue-and-groove effects the collimator was set at 30 de-
grees and the collimator jaw tracking was activated. Figure 8 gives a general illustration 
of the beam setup in 3 different planes, together with 3D reconstructed image. This was 
applied for every plan. To better control the dose conformity in the target, the field size 
was controlled by using the BEV graphics. Maximum field size used in each plan is 
shown in table 4. 
 
 
 
Figure 8. Beam setup (the yellow arc) viewed from different planes: a) transversal, b) frontal, 
and c) sagittal. The red contour represents the PTV and gray area represents the GTV. d) 3D 
modeling where the arc of the beam delivery is shown in red. 
 
Table 4. Maximum field size for different PTVs and fraction sizes. 
PTV d(cm)_dose fraction (Gy) 3_4 3_7.5 3_11 3_18 6_4 6_7.5 6_11 6_18 
Field size X*Y (cm2) 4x3.8 3.2x3.3 4x4.5 4x4.5 7x7.5 7x7.5 7x7.5 7x7.5 
 
b) 
d) 
a) 
c) 
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Isocenter of the plans was located at PTV’s center point. The selected dose rate was 
the nominal one, 1400 MU/min. In general, the dose/fraction used clinically for SBRT 
treatments depends on the stage and location of the tumor. In this work, the applied 
fractionation scheme for each PTV was 8x7.5 Gy, 5x11 Gy and 3x18 Gy. These values 
are also the most typical ones used in the department and also have been used in other 
centres [4; 29; 30]. In addition to these values, more conventional fractionation of 15x4 
Gy was added in the study. Because it is a small dose/fraction, it cannot be considered 
for SBRT treatment. However, this addition was done for study purposes only. 
3.3. Optimization of dose distribution 
After the beam setup, for each plan, the individual optimization of dose distribution for 
each dose level followed. VMAT optimization options such as the upper objectives, 
lower objectives and priorities were selected keeping in mind the RTOG 0915 protocol. 
This protocol which is widely consulted for SBRT treatments, suggested that several 
criteria have to be met for the clinical dose calculation to be acceptable. The criteria 
used in this thesis concern mainly the dose conformity evaluation. The ones concerning 
the organs at risk are neglected because they are irrelevant to the scope of the work. 
Therefore, the standards used here are: 95 % of the target volume (PTV) receives 100 % 
of the prescribed dose and 99 % of the volume receives at least 90 % of the prescribed 
dose. The volume of the 105 % of the prescribed dose outside the PTV should not be 
more than 15 % of the PTV volume [16] and the maximum dose inside the PTV should 
be between 110 % and 140 % of the prescribed dose [30]. These were the initial values 
plugged in the optimization window; however, to achieve a better dose conformity, they 
were slightly adjusted and some iterations were performed.  
 
Figure 9. Normal Tissue Objective parameters chosen during the dose distribution calculation. 
a) graphic representation, b) selected parameters.  
Optimization process computes the optimal fluence maps which is then converted 
into the actual fluence maps via the MLC system. To get a sharp fall-off dose outside 
the target volume, NTO parameters were selected as shown in figure 9 and the priority 
[cm] 
[cm] 
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for “normalization tissue” was set to be high. The X and Y jaws were kept dynamic, 
thus their aperture depended on the field size and MLC motion.  
After all parameters were defined, calculations for the optimized plans were gener-
ated using AAA algorithm with grid size 0.25 cm and with tissue heterogeneity consid-
eration. The use of grid sizes greater than 3 mm is discouraged for SBRT [30]. In this 
process, several data were calculated, including here the amount of MU used for each 
field, the dose received from the target, lungs and body, respectively. Dose normaliza-
tion was chosen such that 95 % of the target receives 100 % of the prescribed dose.  
3.4. Plan evaluation and verification 
After the computations were completed, the plan evaluation was performed both visual-
ly and numerically. In TPS visual evaluation was done by checking the dose conformity 
within the target and the location of the hotspots. As for the numerical evaluation, 
isodose levels were accounted as well as dose statistics such as minimum, maximum 
and mean dose for each PTV. 
A very common method to check the dose distribution in every structure is the 
DVH. It displays the dose distribution uniformity with regard to the structures’ volumes 
in a 2D graph. In one single line it gives a very good evaluation of dose distributions for 
every structure involved in the dose calculation. It does that for one or more plans at 
once. For external beam radiotherapy, there are two types of DVH: cumulative and dif-
ferential. Cumulative DVH shows the relative (in %) or absolute (in cm
3
) volume of the 
structure receiving a predefined dose. The structure volume in % or cm
3
 is given in the 
Y-axis and the X-axis represents the amount of dose either in % or in Gy. On the other 
hand, the differential DVH illustrates the share of the accumulative volume in structures 
receiving a particular dose with regard to equivalent dose intervals. In this thesis, the 
cumulative DVH is used. Sharper the curve drops down, the better is the dose uniformi-
ty [11]. 
Plan verification was the next step taken. Verification plans are created with the aim 
of verifying the accuracy of the treatment plan prior to patient treatment. It contained 
the same beam size, beam energy and angle as in the original patient plan, including 
here also the amount of used MU, field accessories, fluencies and MLC motions. In 
addition, the phantom was located at the isocenter exactly as the planned patient. For 
each of the treatment plans, the verification plans were created using the solid water 
phantom which CT images were priorly taken. 
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3.5. Dosimetric Verifications 
The verification plans were transferred to the Varian TrueBeam STx linac machine 
which was calibrated to deliver 100 MU per 1 Gy for a field size of 10x10 cm
2
 and 
SSD=100 cm at depth of maximum dose. The MLC system contained 120 high defini-
tion leafs (HD-MLC) with leaf width of 2.5 mm (32 of them per bank) and 5 mm (28 of 
them per bank), leaf transmission less than 2 %, minimum dynamic leaf gap of 0.25 mm 
and maximum leaf speed of 2.5 cm. Dose rates supported for FFF beam were 1400 and 
2400 MU/min for 6 MV and 10 MV, respectively. During the dose delivery, based on 
the data coming from TPS, linac coordinates three parameters: gantry speed, dose rate 
and MLC speed. Then the dose is delivered through the CP within the arc segment and 
between these points interpolation was performed. Because of the high complexity of 
the delivery, verifications of the dose distribution (usually in 2D) are always required. 
There are several options used to measure 2D dose distributions: films, ionization 
chambers, ionization chamber arrays, electronic portal imaging devices (EPID), radio-
graphic and radiochromic films [31]. Each of them has their own advantages and limita-
tions. For example, EPID offers very good resolution and real-time analysis but it could 
not be used in the current measurements because there is no proper model of it for FFF 
beams, yet. For the current study, the verification and accuracy of the delivery, com-
pared to the calculations was made using two different types of dosimetry: ionization 
chamber matrix detector (combined with cubic solid water phantom and mounted in the 
gantry) and radiochromic films. In each case, the calculated dose maps were exported to 
the OmniPro Im’RT software version 1.7 (IBA Dosimetry, Schwarzenbruck, Germany). 
To be able to compare measured (both from detector and radiochromic film) and calcu-
lated data with each other, the grid size of each of them had to be converted into a 
common spatial resolution. The grid conversion based on linear interpolation was done 
from 0.7619 cm to 0.1 cm for measured data and from 0.047 cm to 0.1 cm for calculated 
data.  
3.5.1. Matrix detector on treatment couch 
In the first scenario, shown in figure 10, the I’mRT ion chamber matrix detector (IBA 
Dosimetry, Schwarzenbruck, Germany), commercially named as MatriXX
Evolution
 
(which from now on will be referred to as MXX) is used. MXX is a 2D digital verifica-
tion system supported from the OmniPro I’mRT software. It is used for the verification 
of 2D dose distribution and usual for the quality assurance (QA) of high energy photon 
and electron beams, before the treatment. It is composed of 1020 ionization chambers 
with individual volumes of 0.08 cm
3
. Chambers were organized in a 32 x 32 matrix with 
gap between them equal to 0.7619 cm. The chambers are ionized when the photon beam 
goes through them and with the help of an electrical field the released charge is divided 
between the upper and lower electrodes. The current in the chambers is proportional to 
the dose rate falling into the matrix. The current is estimated and converted into a digital 
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signal thus giving information on the dose rate in each chamber. Further technical de-
tails are given in table 5. 
 
Figure 10. MCube-MXX setup on the treatment couch.Detector is sandwiched between the 
MCube phantom, on the treatment couch. The gantry irradiates the phantom while rotating, as 
planned. 
MXX was then inserted into a solid water phantom, called MULTICube Lite (IBA 
Dosimetry, Schwarzenbruck, Germany). Its size was 31.4 cm in length by 34 cm in 
width by 21 cm in height. It is made of polystyrene with mass density of 1.04 g/cm
3
 
with 11 cm above and 10 cm under the matrix detector. Solid water plates seen in the 
image were used only to support the electronic part of the detector and had nothing to 
do with the measurements. MXX was calibrated for FFF beam and open field of 10x10 
cm
2
 and before the measurement, the matrix was warmed up for 15 minutes, as recom-
mended from the manufacturer [32]. 
Table 5. Technical data on the MatriXX
Evolution
 used for the measurements. 
Item Characteristics 
Sensor type Vented parallel ion chamber 
Number of sensors 1020, arranged in a 32x32 grid 
Active measurement area 24,4x24,4 cm 
Chamber diameter 4.5 mm 
Chamber height 5 mm 
Chamber volume 0.08 cm
3 
Distance between chambers 7.619 mm 
Minimum dose rate 0.02 Gy/min 
Maximum dose rate 20 Gy/min 
Water equivalent depth 3.2 mm 
MULTICube Lite
 
MatriXX
Evolution
 detector
 
Gantry
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The gantry and collimator angles of the linac were set to 0 degrees and the matrix 
was positioned on the treatment table in the centre of the beam with the guidance of 
light field. Then, MXX was connected with the computer in the control room through an 
Ethernet cable. Distance between the effective point of the MXX and the beam source 
was kept at 100 cm. 
Due to the complex construction of the matrix detector, the sensitivity of the pixels 
is slightly affected from the beam coming at different angles during the gantry rotation 
and this dependency may influence the measured results. Therefore, a gantry angle sen-
sor was attached to the gantry for angle estimation. Its purpose was to correct the meas-
urements for angular dependence during the gantry rotation with the correction factors 
provided by the vendor. Finally, irradiation was performed as in patient actual treat-
ments with gantry roatating around the phantom. 
     
Figure 11. Angle sensor mounted on the gantry and connected with the detector. Adopted from 
[33] 
3.5.2. Matrix detector mounted on treatment head 
In this case, the MXX is mounted on the treatment head via a dedicated frame. Different 
from the previous case the gantry angle sensor was not used. This is because the gantry 
and the detector were attached to each other such that the beam was perpendicular to the 
detector during the whole radiation and there was no change in the angle between them.  
Moreover, plates which are water-like polystyrene were put between the detector 
and the frame, for a total thickness of 5 cm above the matrix. The isocenter was located 
on the surface of the matrix. Before the measurements took place, MXX was also cali-
brated for the FFF 6 MV beam of field size 10x10 cm. Figure 12 shows the setup of the 
measurement. 
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Figure 12. MXX mounted on the gantry with the help of the dedicated frame. 
3.5.3. Film measurement 
Results of many electronic detectors for dose distribution verifications have been widely 
published. For example, a brief, precise summary of them is given from Poppe et al. 
[34] and as it has been reported, due to the high spatial resolution, film measurement is 
the standard and the most accurate method for 2D dose distribution verifications. Its 
major disadvantage is the film procedures being very time and material consuming. 
Moreover, these procedures (for example calibration, scanning, and irradiation) require 
very high accuracy and stable chemical processing techniques.  
In this thesis, radiochromic films EBT-3 (International Speciality Products, Wayne, 
USA) with size of 20.3x25.4 cm
2
 and an external flatbed scanner, Epson Dual Lens  
System-V700 Photo, (Epson, Seiko, Nagano, Japan) with 12-bit pixel depth and resolu-
tion 6400 dots per inch are used. Up to date this film is the latest update among the   
radiochromic films and performs quite well. Some of its advantages are: symmetric 
structure (eliminates the problem of which side of the film has to be scanned); elimi-
nated Newton’s Rings patterns (created from the light reflection between two surfaces 
located close to each other, one spherical and one flat) and dose rate independency [35]. 
Its main disadvantage is the lengthy time procedures and very high precision required 
during its use.  
Calibration 
For the current measurements, films required calibration prior to any plan irradiation. 
Film calibration is required in order to convert the optical density into absorbed dose 
where the dose delivered is related to the darkness of the film. It is defined as shown in 
equation 8 
OD=log(I0/It)   (8) 
Gantry 
Fixing frame 
MXX 
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Where I0 is the intensity of light falling on a certain region on the film and It is the 
intensity of light transmitted through the same region. [1.] The film intended for calibra-
tion was first digitzed by using the Epson scanner. This was done to define the back-
ground correction which minimizes the uncertainties during the scanning. The correc-
tion factor is calculated by subtracting the pre-exposure values from the post-exposure 
ones. Next, the same film was cut in 9 equal pieces of 5x5 cm
2
. To create the film re-
sponse curve, all films were irradiated with known doses. Figure 13 shows the irradiated 
films. The same physical arrangement was used also for the digitization of them with 
the scanner. Before irradiation, the known dose to be delivered was planned in TPS for 
each film. Table 6 presents the assigned MU for each film and the resulted dose in Gy.  
 
Figure 13. Irradiated films with the known doses in the same arrangement they were scanned. 
Table 6. These are the calculated values for each film. The amount of MU dedicated to each of 
them and the calculated dose delivered accordingly. 
Step 1 2 3 4 5 6 7 8 9 
MU 0 20 50 90 150 250 400 600 800 
Dose (Gy) 0 0.17 0.424 0.764 1.273 2.121 3.394 5.091 6.788 
Every film was then irradiated for the planned doses with the Varian linac 6 MV 
FFF with dose rate 1400 MU/min at SSD of 100 cm and field size of 10x10 cm
2
. One of 
the scanned films was not exposed to any radiation and is used for fog determination. 
Each other film was individualy inserted within the MCube which was standing on the 
treatment couch (same setup as in section 3.5.1). The position of the film within the 
phantom was important to remain static and vacuum free from the surface, during the 
treatment. Consequently, each film was marked and positioned with regard to the origin 
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of the phantom. The position of the markers was then used in the film setup, preceding 
the analysis. The whole process is reliant on film’s sensitivity, which depends signifi-
cantly on the age, type, batch and storage conditions of the film. 
Different films have different sensitivities thus the calibrations vary. That is why in 
the measurement setup, the calibration parameters were stored together with the film 
type. After the irradiation, films were put in a closed box where they stayed 18 hours 
until the scanning process. During this time, the active component of the film is polym-
erized progressively. The amount of polymerization and optical density increases as the 
dose delivered increases [36]. This explains the different colors observed for each film 
as shown in figure 13. Film development continues indefinitely, but decreases with time 
and for acceptable results, there is always a recommended film developing time. 
All nine films were digitized by scanning all of them at once at the center of the 
scanner. In addition, the scanner artefact correction was applied because there was a 
chance that artefacts are created from the scanner’s light during the film scanning. The 
calibration data were displayed as given in table 7 and saved to the OmniPro I’mRT 
database. ADC stands for analog-to-digital converter and the shown values were used 
for such conversion. In addition, based on the results given from Casanova, et al. [35.], 
each film consists of three main channels, red, green and blue with the red channel hav-
ing a better response, up to 10 Gy, compared to the green and blue ones. Green channel 
becomes better than the red one for doses higher than 10 Gy and blue channel does not 
overtake any of the other two in any case. Keeping in mind that, the only dose/fraction 
used in the current measurement was 4 Gy, thus the red channel was utilized.  
Table 7. Calibration data used for film calibration. Each step (film) is associated with the dose 
delivered into them and the correnspondent analog to digital converter (ADC) value. 
Step 1 2 3 4 5 6 7 8 9 
ADC 24169 25905 28490 30760 34282 38391 42093 46610 48703 
Dose (Gy) 0 0.17 0.424 0.764 1.273 2.121 3.394 5.091 6.788 
 
Dose distribution measurement  
After the calibration was complete, the dose distribution of PTV 3 for dose/fraction of   
4 Gy was performed. A film from the same batch as the calibration one was picked and 
a similar procedure as for the calibration was performed. More specifically, the film was 
digitized on the Epson scanner for fog determination. Then, it was cut in half (sufficient 
for the current field size) and mounted within the MCube Lite. The phantom itself was 
positioned on the treatment table exactly as described in section 3.5.1. When the irradia-
tion was completed, the film was put carefully in a closed box. To achieve the best re-
sults from film measurements, Aland, et al. [37] suggested that measurement film and 
calibration film should have the same film developing duration, which was 18 hours.  
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After 18 hours of film developing (on its own), the film was digitized with the same 
scanner as before. For every scanning, the scanner was warmed up prior to the scanning. 
For the reason mentioned before, the red channel of the film was used. Then, the 
scanned image was imported to OmniPro Im’RT software. The scanner correction fac-
tors were calculated from the empty film scanned previously and then they were applied 
to the image containing the dose distribution. The calibration curve estimated from the 
calibration process was utilized on the film containing the dose distribution. Finally, the 
calibrated film was digitaly saved and was ready for comparison with the calculated 
dose distribution.    
3.6. Dose distribution evaluations 
To provide dose distribution measurements, matrix detector and radiochromic films 
were used. However, one of the challenges of these methods is the large amount of 
measured and calculated points and their analysis. Therefore, tools for such analysis 
have been developed and one of them being the gamma analysis. It is widely used to 
compare the calculated dose distribution with the measured one for every point [38]. 
The idea was introduced in 1998 from Low et al. [39] and is based on two different 
evaluation types, namely dose difference, given from equation 9, and distance-to-
agreement (DTA). The former gives the dose difference of the respective points from 
both dose distributions as  
Dose difference=Dc(rc) – Dm(rm)    (9) 
Symbols Dc(rc) is the calculated dose at rc in the calculated plan and Dm(rm) is the dose 
at rm in the measured distributed dose. In addition, rm is the location of a particular 
measurement point and rc is the spatial location of the calculated distribution with re-
gard to the measured point, rm. 
On the other hand, DTA gives the distance between a measured dose point and the 
closest calculated dose point having the same dose value, known also as isodose       
distance. Keeping in mind the same notations as earlier, DTA is given from equation 10. 
                         (10) 
However, both techniques have their own limitations. The dose difference works 
well in low gradient regions, but it is not as efficient in high gradient ones because any 
small misalignment results into a large difference. Whereas, the DTA works correct in 
high gradient regions (the corresponding dose level is still close by) but not in small 
gradient ones because it usually takes a large radius to find the matching dose levels 
even though the misalignment would be small. [1.] 
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To solve the problem of different sensitivities, a common equation, as shown from 
equation 11, was developed. It combines the two techniques and is applied for every 
reference point independently. Because the techniques have their limitations in different 
dose gradients, this analysis uses one technique in the region where the other tends to be 
over sensitive and fails to meet the criteria. When both parameters fail, the compared 
points fail the test.  
          
         
   
  
       
 
   
    (11) 
 and                          
The first numerator within the square root sign belongs to DTA. The second one 
corresponds to the dose difference. The threshold ∆dM is for passing the isodose criteria 
and ∆DM is for passing the dose threshold. [39.]  
After the normalization of both components, Γ is obtained by squaring their values, 
summing them up and taking its square root, as shown in equation 10. In the end, the 
gamma index, γ is given as the smallest value of Γ with the distance r changing when 
the checking is done by going through the isodose line to find the point where DTA is 
minimal. The deal is that when γ(rm) is equal to or larger than 1, the calculation fails and 
if γ(rm) is smaller to 1 then the calculation passes. If DTA and dose difference are both 
on the limit, equal to 1, the test is considered as “fail” because the γ=√2. In other words, 
γ provides a single evaluation value, instead of two and it also takes care of the regions 
where any of the components would perform poorly. [39.] 
There is no strict rule in choosing the thresholds for dose difference and DTA be-
cause it depends on the case study and relavant experience. However, a general case 
which is also applied for the comparison of the current calculated and measured data is 
3 mm for DTA and 3 % for the dose difference. The size of region of interest (ROI) was 
24 by 24 mm, relevant signals ≥ 50 % and search distance 4.5 mm (searching is stopped 
after 4.5 mm).  
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Figure 14. Example of the beam profile and its main components.Adopted from [40]. 
Gamma analysis gives an overall feedback on the relation between the measured and 
calculated data. To understand in more detail how well these data fit with each other, 
dose profile evaluation is needed. Dose profile describes how the dose is altered in the 
plane perpendicular to the central beam axis at an arbitrary depth. It consists of three 
main regions, central dose region, penumbra and umbra, as shown in figure 14 [6].  
 
To give a very general evaluation over the comparison between measured and calcu-
lated data, accuracy criteria proposed by TRS 398 limitations were used. The difference 
with gamma analysis is that the latter shows the difference for individual points while 
TRS 398 is concernced mainly for the disagreement level between measured and calcu-
lated dose profiles taken as a whole. TRS 398 concluded that there were no definite  
exact limitations to be applied for the differences between the data, however, based on 
experience, the average uncertainties should preferably be within 5 %. Finally, the glob-
al average uncertainties of all cases should be as well not higher than 5 %. [41.] The 
average uncertainty between measured and calculated data for each case was generated 
by converting the grid size of calculated data to 0.7619 cm resolution and keeping the 
grid size of measured data unchanged (by default was 0.7619 cm). This conversion was 
made so the calculated data had the same spatial resolution as the measured one. Final-
ly, the dose difference was estimated in different points of the high dose regions and 
their average value was calculated. 
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4. RESULTS 
4.1. Calculated dose distributions 
Dose conformities together with the dose-color legend for both PTVs for dose/fraction 
of 4 Gy and 18 Gy are given in figures 15 through 18. PTV volume is represented by 
the outer red contour and the respective GTV with the inner contour. From the thesis 
perspective, one could notice that dose distributions within the target seem to be quite 
conforming. Dose is concentrated within the target and RTOG requirements were met: 
maximum dose in PTV was between the required limits of 110 % and 140 % of the  
prescribed dose and the volume of 105 % of the prescribed dose outside the target did 
not exceed the threshold of 15 % of the PTV volume. This was the case for all plans and 
for display purposes PTVs with the lowest (4 Gy) and highest dose/fractions (18 Gy) are 
presented only (figure 15-18).  
 
 
Figure 15. Dose conformity in PTV 3 for dose/fraction of 4 Gy. PTV is modelled as the outer 
contour and GTV as the inner one. Viewing planes are a) transversal, b) frontal and c) sagittal. 
The percentage shows the maximum dose within the volume which is within the RTOG limits. 
The maximum dose in percentage a) 125.9 %, b) 136.7 %, c) 137.2 % shows the maximum dose 
within the target volume which were within the RTOG limits and d) gives the color legend cor-
responding to the prescribed dose. 
 
Figure 16. Dose conformity in PTV 3 for dose/fraction of 18 Gy. PTV is modelled as the outer 
contour and GTV as the inner one. Viewing planes are a) transversal, b) frontal and c) sagittal. 
Percentage a) 131.7 %, b) 137.3 %, c) 137.5 % shows the maximum dose inside the target vol-
ume, which were within the RTOG limits; d) gives the color legend corresponding to the pre-
scribed dose. 
a) b) c) 
a) b) c) 
d) 
d) 
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Figure 17. Dose conformity in PTV 6 for dose/fraction of 4 Gy. PTV is modelled as the outer 
contour and GTV as the inner one. Viewing planes are a) transversal, b) frontal and c) sagittal. 
Percentage a) 133.6 %, b) 133.2 %, c) 132.1 % shows the maximum dose inside the target vol-
ume, within RTOG limits and d) gives the color legend corresponding to the prescribed dose. 
 
 
Figure 18. Dose conformity in PTV 6 for dose/fraction of 18 Gy. PTV is modelled as the outer 
contour and GTV as the inner one. Viewing planes are a) transversal, b) frontal and c) sagittal. 
Percentage a) 134.8 %, b) 136.7 %, c) 136.2 % shows the maximum dose inside the target vol-
ume, within RTOG limits and d) gives the color legend corresponding to the prescribed dose. 
The hot spots usually seen in the target volumes are considered to be positive as 
long as they are within the GTV and do not reach the normal tissues. The ones located 
in the center of the volume are even better because of their high efficiency to break the 
resistance of the tumor, most likely situated within the same region. [2.] 
DVHs displayed in figure 19 and 20 show the uniformity of the dose within the PTV 
and GTV. The steeper the PTV graphs the better dose uniformity. Figure 19 corre-
sponds to PTV 3 (red) and its respective GTV (pink); the relative dose in percentage is 
given with regard to the structure volume also expressed in percentage. For display  
purposes, cases of 4 Gy and 7.5 Gy were combined together and the ones of 11 Gy and 
18 Gy were combined in one graph. The same was applied for PTV 6 and its respective 
GTV in figure 20. As it can be observed, for each case, the RTOG requirements were 
met: 95 % of the target volume (PTV) receives 100 % of the prescribed dose and 99 % 
of the volume receives at least 90 % of the prescribed dose. 
a) b) c) 
b) a) c) 
d) 
d) 
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Figure 19. The combined histograms for PTV 3(red) and the respective GTV (pink). The 
dose/fractions for each of them are a)     =4 Gy and     =7.5 Gy, b)     =11 Gy and    = 18 Gy. 
RTOG protocol requirements were met. 
  
a) 
b) 
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Figure 20. The combined histograms for PTV 6 (red) and the respective GTV (magenta/pink). 
The dose/fractions for each of them are a)      stands for 4 Gy and     stands for 7.5 Gy,             
b)       represent 11 Gy and      represent 18 Gy. RTOG protocol requirements were met. 
 
4.1.1. Delivery time and the amount of monitor units 
The time required for the delivery of the prescribed dose and the amount of monitor 
units used for each PTV are given in table 8. As it is expected, for the same PTV, higher 
the dose/fraction, longer the delivery time. The same can be concluded when the 
dose/fraction remained unchanged and PTV diameter increased. It was noticed that if 
the same dose/fraction is used for the two different PTVs then there is a small time   
advantage when small PTV was irradiated. The dose delivery time for each case was 
considered as clinically acceptable. 
 
b) 
a) 
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Table 8. Results concerning the amount of monitor units (MU) and delivery time (min) for each 
PTV and dose/fraction. 
PTV_Dose/Fraction 3_4 3_7.5 3_11 3_18 6_4 6_7.5 6_11 6_18 
Monitor Units, MU 913 2286 2337 3885 1025 1761 2501 3930 
Time, min 0.66 1.14 1.67 2.78 0.75 1.26 1.79 2.81 
4.2. Dosimetric verifications 
4.2.1. Matrix detector on treatment couch 
Results gained from the matrix detector were in general acceptable, especially for the 
large field sizes (from PTV 6). The dose level of measured profile was in very good 
agreement with the calculated one for PTV 6 but not as good for PTV 3 where smaller 
field sizes were used. This can be checked both visually and numerically (average dose 
differences collected for the high dose region of the signal). These values for PTV 6, 
based on the TRS 398 protocol, were generally within the suggested limits while for 
PTV 3 were slightly above these limits. The reason why these average values are not 
smaller was because of some peak deviations in the corners of high dose region. Details 
for each case are explained next.  
 
Figure 21. a) Gamma analysis for the compared data corresponding to PTV 3 and 
dose/fraction=4 Gy b) direct comparison between measured (red) and calculated (green) dose 
profiles in Y-direction. Dose difference at the center of the dose map was at maximum of 7.5 % 
and the average dose difference calculated for the signal above 90 % was 6.0 %. 
Figure 21a) presents the gamma analysis of the measured and calculated results for 
the PTV 3 irradiated with 4 Gy/fraction. As the legend in the figure illustrates, gamma 
values larger than 1 are marked as fail (red), pass if smaller than 1. Meanwhile figure 
21b) demonstrates the profile comparisons between measured (red) and calculated 
(green) results. Here, only the profiles in the Y-direction are illustrated because of the 
higher differences observed compared to the ones in the X-direction. These profiles are 
the ones seen from Y-direction at position (0, 0) in the 2D dose gamma map. Further-
more, one can also notice which part of the profiles are relevant to the gamma analysis, 
merely by synchronizing the Y-axes of both figures. Thus, as seen from both figures, 
the major disagreements, given in red, come from the central dose region where the 
b) a) 
Y 
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peak difference (measured-calculated) between the data was 7.5 %. Yet, the average 
dose difference calculated for ROI occupying high dose region of the signal was 6.0 %.  
Figure 22 reveals information for PTV 3 and dose/fraction of 7.5 Gy. According to 
gamma analysis, the disagreement comes from the high dose region of the profiles 
where the maximum dose difference reaches up to 8 %. The average dose difference 
was about 7.6 % which was above the suggested limit as well.  
 
  
Figure 22. a) Gamma analysis for the compared data corresponding to PTV 3 and 
dose/fraction=7.5 Gy b) direct comparison between measured (red) and calculated (green) dose 
profiles in Y-direction. Dose difference at the center was about 8% and the average dose differ-
ence calculated for the high dose region of the signal was 7.6 %. 
 
Figure 23 shows the dose distribution comparison for PTV 3 and dose/fraction equal 
to 11 Gy. The situation seems to be similar to the previous ones, in which the main dif-
ference is located in the high dose region while the rest appeared to have better agree-
ment. The dose difference in the centre is about 6.5 %, in the lateral horns varies from 
3.3 to 6.6 %. These maximal disagreements were large enough to generate inadequate 
average value of 5.2 %, calculated for the high dose region.  
 
 
Figure 23. a) gamma analysis for the compared data corresponding to PTV 3 and 
dose/fraction=11 Gy b) direct comparison between measured (red) and calculated (green) dose 
profiles in Y-direction. Dose difference at central area is about 6.5 %, at the lateral horns var-
ied between 3.3 and 6.6 % and average dose difference equal to 5.2 % for ROI occupying the 
high dose region of the signal. 
 
a) 
a) b) 
b) 
Y 
Y 
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Images of figure 24 correspond to PTV 3 and dose/fraction of 18 Gy. The same 
phenomena was noticed, the failed agreement was located in the central area of the 
gamma map, central dose region, with approximated dose difference equal to 4.3 %. On 
the other hand, the average value of disagreement for ROI covering high dose region of 
the signal was 5.8 %.  
 
 
Figure 24. a) gamma analysis for the compared data corresponding to PTV 3 and 
dose/fraction=18 Gy b) direct comparison between measured (red) and calculated (green) dose 
profiles in Y-direction. Dose difference at the center was about 4.3 % with the average one be-
ing 5.8 % for ROI covering the high dose region of the signal. 
The dose distribution comparison, gamma analysis associated with an example con-
taining the dose profiles of measured and calculated data for PTV 6 and dose/fraction 
equal to 4 Gy is shown in figures 25. Both images show that the disagreements appear 
to be concentrated in almost the whole central dose region. This can be verified by sim-
ply checking the location of this region in the profile, being roughly between -3 and      
3 cm in the Y direction and comparing it with the same region in the gamma map, 
where one can see that roughly in the same region and direction the red area is.  The dif-
ferences in the central dose region ranged between 3.5 % and 5.5 % and in the lateral 
horns it varied between 1.2 % and 3.5 %. These peak values together with other ones in 
the high dose region generated an acceptable average dose difference of 4.7 %. 
 
Figure 25. a) gamma analysis for the compared data corresponding to PTV 6 and 
dose/fraction=4 Gy b) direct comparison between measured (red) and calculated (green) dose 
profiles in Y-direction. Dose difference at the center was between 3.5 and 4.5 % while in the 
lateral horns varied between 1.2 and 3.5 %. Average dose difference was 4.7 % for ROI concen-
trated above 87% of the signal. 
b) 
b) 
a) 
a) 
Y 
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Figures 26, 27, 28 show the results for dose/fraction of 7.5 Gy, 11 Gy and 18 Gy 
applied on PTV 6, respectively. Dose differences for the case of dose/fraction equal to   
7.5 Gy were mainly between the central axis and the lateral horns, about 6 % in both 
sides, as illustrated from the obvious discrepancy in figure 26. The average one was   
3.6 % considering ROI above 90 % of the signal.  
 
Figure 26. a) Gamma analysis for PTV 6 and dose fraction of 7.5 Gy and b) direct comparison 
between measured (red) and calculated (green) dose profiles in Y-direction. Dose difference at 
the center was low between 3.5 and 4.5 % while in the lateral horns reached about 6 %. Aver-
age dose difference was at the acceptable level of 3.6 % for ROI of above 90 % of the signal. 
For the case of 11 Gy, given in figure 27, the dose differences between the measured 
and calculated results were concentrated in the central dose region and were similar to 
the previous case with the maximum reaching at 6 % in the high dose region. However, 
the average dose difference was 4.5 % for ROI being above 90 % of the signal.  
 
Figure 27. a) Gamma analysis for PTV 6 and dose fraction of 11 Gy and b) direct comparison 
between measured (red) and calculated (green) dose profiles in Y-direction. Dose difference at 
the center was on average about 3.5 % while in the lateral horns was negligible. Average dose 
difference was 4.5 % for ROI of above 90 % of the signal. 
 
 
 
 
 
 
a) b) 
a) b) 
Y 
Y 
 47 
 
Finally, the last case concerning PTV 6 and dose/fraction of 18 Gy is given in figure 
28. The same pattern as for the previous cases of PTV 6 was observed. The main dose 
difference concentrated on the high dose region, with the maximum reaching 5.2 % and 
the average being 3.8 % for ROI above 90 % of the signal. 
 
 
 
Figure 28. a) Gamma analysis for PTV 6 and dose fraction of 18 Gy and b) direct comparison 
between the dose profiles of measured (red) and calculated (green) in Y-direction. Dose differ-
ence at the center was on average about 3.5 % while in the lateral horns was negligible. Aver-
age dose difference was 3.8 % for ROI higher than 90 % of the signal. 
 
4.2.2. Matrix detector mounted on treatment head 
Results shown next are from the measurements done with MXX mounted on the gantry.  
Gamma analysis with regard to PTV 3 and dose/fraction of 4 Gy is illustrated in figure 
29a). Figure 29b) reveals the comparison between the profiles in Y-direction. Results 
demonstrated that the major disagreements between measured (red) and calculated 
(green) data came from the central dose region, including lateral horns and central area. 
Dose differences between the data were 8-9.5 % in the lateral horns and about 6 % in 
the central area. In general these values were unacceptable and so was the average dose 
difference, 6.2 % noticed for ROI above 90 % of the signal. 
 
Figure 29. a) Gamma analysis of the compared data for PTV 3 and dose/fraction=4 Gy,           
b) direct comparison between measured (red) and calculated (green) dose profiles in                
Y-direction with dose differences 6 % and 8-9.5 % at the center and lateral horns, accordingly. 
Average dose difference was 6.2 % for ROI higher than 90 % of the signal. 
a) b) 
a) b) 
Y 
Y 
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Figure 30 gives the compared results for PTV 3 and dose/fraction of 7.5 Gy.       
Obviously, the difference between measured and calculated data was negligible and 
certainly within the acceptable suggested limits. However, the average dose difference 
for the high dose region, calculated as explained in chapter 3.6, gave a contradictory 
value of 6.2 %. Figure 30c shows the dose levels from which the average dose differ-
ence was calculated. It is obvious that these two graphs have significant differences be-
tween each other. Two main reasons were thought to explain such contradiction. First 
one was thought to be the different grid size of the calculated data. In figure 30b the grid 
spatial resolution was 0.1 cm and in figure 30c it was 0.7619 cm. The linear interpola-
tion used in these different grid sizes produced irrational results, especially for small 
field sizes. The second reason was the poor resolution of the matrix detector, combined 
as well with the small field size. A study related to the first problem is currently going 
on in the clinic and initial results had supported such dependency.  
  
 
 
Figure 30. a) Gamma analysis of the compared data for PTV 3 and dose/fraction=7.5 Gy,       
b) direct comparison between measured (red) and calculated (green) dose profiles in                 
Y-direction. There is no significant discrepancy between them and the grid size was 0.1cm c) the 
dose profiles from which the average dose difference, 6.2 %, was calculated for the high dose 
region of the signal. Grid size was 0.7619 cm. 
 
 
 
b) a) 
c) 
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Figure 31 gives the results for the compared data concerning PTV 3 and 
dose/fraction of 11 Gy. Results are similar to the case of 4 Gy of the same PTV (figure 
29). Hence, the problem remains the same; the disagreements come from the central 
dose region: central part and lateral horns. The dose differences for dose/fraction of      
11 Gy with regard to the central area and lateral horns were 4 % and about 9.5 %,     
accordingly and the average dose difference was 7 % for ROI covering high dose region 
of the signal. 
 
Figure 31. a) Gamma analysis of the compared data for PTV 3 and dose/fraction=11 Gy.        
b) a direct comparison between the dose profiles of measured (red) and calculated (green) in Y-
direction. Dose differences at the central area was 4 % and at lateral horns about 9.5 %.  Aver-
age dose difference was 7 % for ROI of high dose region of the signal. 
 
As for the dose/fraction equal to 18 Gy, given in figure 32, the differences were slightly 
smaller than previously, 3.5 % and 8.5 % to the central area and lateral horns, accord-
ingly. The average dose difference was at unacceptable levels of 6.7 % for ROI of high 
dose region of the signal. 
 
Figure 32. a) Gamma analysis of the compared data for PTV 3 and dose/fraction=18 Gy.         
b) direct comparison between measured (red) and calculated (green) dose profiles in                
Y-direction. Dose differences of 3.5 % and 8.5 % were recorded at the center and lateral horns, 
respectively. Average dose difference was 6.7 % for ROI covering the high dose region of the 
signal. 
 
 
 
a) b) 
c) d) 
Y 
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Figures 33 through 36 illustrate results regarding PTV 6 for dose/fractions of 4 Gy, 
7.5 Gy, 11 Gy and 18 Gy, respectively. As it can be noticed, the problem was the same 
as in the previous results. The main dose differences came from the high dose region 
(center and lateral horns). Dose differences for dose/fraction of 4 Gy at central region 
and lateral horns were approximately 3 % and 7-8.5 %. Average dose difference was 
estimated to be 4.5 % for ROI above 80 % of the signal, which was still within the   
suggested TRS 398 standards. 
 
 
Figure 33. a) Gamma analysis of the compared data for PTV 6 and dose/fraction=4 Gy,           
b) direct comparison between measured (red) and calculated (green) dose profiles in               
Y-direction as shown from the crosshair in the dose map. Dose differences in percentage for 
central region and lateral horns are 3 % and 7-8.5 %, accordingly. Average dose difference 
was 4.5 %. 
Dose differences for PTV 6 and dose/fraction of 7.5 Gy, in figure 34, appeared to be 
quite similar to the previous case. Dose differences at central region and lateral horns 
were approximately 1-4 % and 7-8 %. Average dose difference was estimated to be 4 % 
for ROI of high dose region. 
 
 
Figure 34. a) Gamma analysis of the compared data for PTV 6 and dose/fraction=7.5 Gy              
b) direct comparison between the dose profiles of measured (red) and calculated (green) in      
Y-direction. Dose differences in percentage for central region and lateral horns are 1-4 % and 
7-8 %, respectively. Average dose difference was 4 % for ROI covering high dose region. 
 
 
 
a) b) 
b) a) 
Y 
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Figure 35 illustrates dose differences for PTV 6 and dose/fraction of 11 Gy. These 
differences at the central region and lateral horns were between 0.5-6 % and 5-11 %. 
Even though, these peak values are above the suggested limits, average dose difference 
was still alright and was estimated to be 4 % for ROI above 90 % of the signal. 
 
  
Figure 35. a) Gamma analysis of the compared data for PTV 6 and dose/fraction=11 Gy,        
b) direct comparison between the dose profiles of measured (red) and calculated (green) in     
Y-direction. Dose differences in percentage for central region and lateral horns are 0.5-6 % 
and 5-11 %, accordingly. Average dose difference was 4 % for ROI above 90 % of the signal. 
 
Figure 36 shows dose differences for PTV 6 and dose/fraction of 18 Gy. As it can be 
noticed, main differences at central region were between 1.5-5 % and at lateral horns 
was 5-10 %. Average dose difference was estimated to be 4.16 % for ROI above 90 % 
of the signal. Table 10 gives a summary of the dose differences in the central region, 
lateral horns and their averages for each measured case.  
 
  
Figure 36. a) Gamma analysis of the compared data for PTV 6 and dose/fraction=18 Gy,       
b) direct comparison between the dose profiles of measured (red) and calculated (green) in     
Y-direction. Dose differences in percentage for central region and lateral horns are 1-5.5 % 
and 5-10 %, accordingly. Average dose difference was 4.16 % for ROI above 90 % of the sig-
nal. 
 
b) a) 
a) 
b) 
Y 
Y X [cm]  
 
X [cm]  
 
 52 
 
Table 9. Summary of the deviations at the central region and lateral horns for both PTVs and 
applied dose/fractions for both detector setups. Average values are added for each setup. Glob-
al average is generated from all the averages of the respective setup. 
 MXX-Mcube Gantry-mounted MatriXX 
PTV_dose/fraction central 
region 
within 
lateral 
horns  
within 
Average 
[%] 
central 
region 
within  
lateral 
horns  
within 
Average 
[%] 
3_4 7.5 %  6 6 % 8-9.5 % 6.2 
3_7.5 8 %  7.6 N* N* 6.2 
3_11 6.5 % 3.3-6.6 % 5.2 4 % 9.5 % 7 
3_18 4.3 %  5.8 3.5 % 8.5 % 6.7 
 Average of the PTV 6.2   6.5 
6_4 3.5-5.5 % 1.2-3.5 % 4.7 3 % 7-8.5 % 4.5 
6_7.5  6 % 3.6 1-4 % 7-8 % 4 
6_11 6 %  4.5 0.5-6 % 5-11 % 4 
6_18 5 %  3.8 1-5.5 % 5-10 % 4.2 
 Average of the PTV 4.2   4.2 
 Global average 5.2   5.4 
* N stands for “Negligible” values. 
 
4.2.3. Film measurement  
Finally, the film measurement results are shown in figure 37. The red profile shows the 
measured data and the green one shows the calculated data for PTV 3 and dose/fraction 
of 4 Gy. It is clear that the absolute dose difference in dose level is quite high, at about 
10 % but the shape of the profile is very similar to the calculated one, as displayed in 
figure 38. Therefore results in terms of of the dose profile can be considered acceptable.  
 
 
 
Figure 37. Comparison between measured (red) and calculated (green) profiles for PTV 3 and 
dose/fraction=4 Gy at Z-direction. It is clear that the difference among them is about 10 %. 
[%] Signal 
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Figure 38. Relative dose comparison. Dose profile shapes between measured (red) and calcu-
lated (green) data are in very good agreement. 
Film measurements for other cases were not implemented because of the unsatisfac-
tory results from the current case. Reasons for such gap between the data are discussed 
in the coming chapter. 
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5. DISCUSSION 
5.1. Dose within the target volume 
From the results presented in this thesis, one could notice that dose delivery within the 
target has been satisfactory. The RTOG requirements were met by simply performing 
few optimization iterations and slight modifications of the objectives for each structure. 
The hotspots were all within the PTV and in most cases even inside the GTV. These 
prominent results were further supported by the outcomes of dose-volume histograms 
where the PTV and GTV both obeyed the RTOG protocol rules. An important role in 
the well dose distribution was played by the dose fall-off gradient. Parameters that in-
fluence the fall-off gradient are the beam energy and MLC leaf width. For small beams 
commonly used in SBRT, the larger the beam energy, the larger the beam penumbra 
broadening due to increased lateral electron transport in medium. Considering that lung 
tissue is a medium of low density, this relationship is emphasized even more. The 6 MV 
beam used in this case was a good trade-off between beam penetration power and pe-
numbra quality. As for the MLC, higher the spatial resolution, better the dose distribu-
tion is. However, this relation is limited by the finite source size and lateral range of 
secondary electrons. For tumors with diameter larger than 3 cm, the MLC leafs em-
ployed by the current linac has been considered to be reasonable [2]. 
 
Another factor contributing in the uniformity of the dose in the target is the avoid-
ance of the organs at risk surrounding the PTV. The introduction of many OARs in the 
optimization process would increase the difficulty of the calculation for the algorithm. 
For example there are tissues with various electron densities, such as hard tissue (for 
example ribs) and soft tissue (for example lungs, heart, and oesophagus) that increase 
the calculation difficulty. Even though it depends on the geometry, energy and number 
of chosen beams, the more different healthy tissues involved, the more complicated the 
algorithm calculation becomes. It does not necessarily mean that the dose distribution 
becomes worse but definitely it would be more challenging for the algorithm to achieve 
the required distribution in a longer time as well. [18.] The OARs and their effects just 
mentioned earlier were skipped because they were irrelevant for the scope of this thesis 
work. As a conclusion, the dose distribution within the target for the purpose of clinical 
commissioning was considered as successful.  
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5.2. Delivery time and monitor units 
The amount of monitor units and dose delivery time dedicated to each plan was con-
sidered to be acceptable and it increased when either the dose/fraction or target volume 
or both increased. In most of the cases, the gantry speed was reduced during the dose 
delivery. Usually in VMAT, the gantry speed is reduced when the fluence delivery is 
higher than what can be delivered at the maximum speed. According to Craft, [14], the 
gantry slows down for two reasons. First one was the very high fluence delivery, as  
explained earlier. The second one was the very high modulation of the fluence map 
[14]. Considering that the current volume was simple (sphere) and no OAR’s were in-
volved, the modulation could not be considered very complex. Therefore, the gantry 
speed was reduced more with higher amount of MUs to be delivered. Moreover, in this 
work, for better comparisons, only one (partial) arc was utilised for each case. If there 
were more than one, the gantry speed for each arc most likely would not be reduced, 
although the total treatment delivery would not change [42].  
 
Another aspect that influences the delivery speed is also the space in degrees be-
tween the control points during the VMAT delivery. The choice of this spacing is a 
trade-off between the accuracy of the delivery and the delivery time. Higher the amount 
of control points, higher the accuracy and longer the delivery time. [43.] The control 
point space in the current work was 2 degrees which is considered to be a practical 
choice for RapidArc treatments and the delivery times noticed in the current measure-
ments were considered clinically acceptable. Compared to 6 MV FFF SBRT VMAT 
delivery times of other studies with larger target volumes and similar monitor units, the 
current values appeared to be reasonable. For example, in Scorsetti’s work [44], the FFF   
6 MV beam on time ranged between 0.9 and 4.4 minutes, for doses ranging from      
3.83 Gy to 12.21 Gy and dose rate of 1400 MU/min. 
5.3. Dosimetric verifications with matrix detector 
The most important results of the thesis were the ones related to the measurements of 
dose distributions. Similar pattern noticed in all of the obtained results was the dis-
agreements between measured and calculated results in the high dose region especially 
when the calculated dose changed rapidly due to the high modulated fluencies. Maximal 
discrepancies were in most cases in the lateral horns and central area of the high dose 
region. However, the average discrepancies noticed in the high dose regions of the dose 
profiles are considered to be more important than the maximal ones. Consequently, the 
evaluation of the comparison between measured and calculated data was based on these 
average values.  
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According to these average discrepancy values, measured profiles were in good 
agreement with calculated one for PTV 6 more than for PTV 3. Average values ob-
tained for PTV 6 in MXX-MCube setup and gantry mounted detector were 4.2 % in 
each case. For PTV 3, these values were 6.2 % and 6.5 %. Global averages for each 
setup were 5.28 % and 5.4 % for MXX-MCube and gantry mounted detector, respec-
tively. TRS-398 standards suggested a passing threshold of 5 % and PTV 6 was the only 
one to be considered as acceptable in this light. Considering that this threshold is only a 
suggestion, global averages could be considered as quite close to the acceptance level.  
Although the average disagreements of PTV 6 were within the limits, reasons of  
unsatisfactory results of PTV 3 and the noticed maximal discrepancies need to be inves-
tigated. Few possible reasons that could explain these differences would be the low spa-
tial resolution of the matrix combined with angle correction factors, small field sizes 
and the interpolation of the calculated data. 
5.3.1. Matrix spatial resolution and field size 
Low spatial resolution of the matrix detector (due to the large distance between detec-
tors) and small field sizes at the same time were considered as significant contributors to 
the unsatisfactory results. In principle, when steep dose changes occured due to the high 
modulated fluence, the demand for better spatial resolution increased. Since the amount 
of ion chambers remains unchanged, the measured dose will differ from the calculated 
one. MXX works based on the direct measurements coming from the ion chambers and 
data interpolation between the chambers. Logically, interpolation is more accurate when 
the measured points are in a straight line or simply a larger amount of them is recorded.  
 
Another factor that emphasized the poor detector’s spatial resolution was the field 
size. As already mentioned, the more densed sampling recorded from the matrix, the 
better interpolation it performs, thus better the results. Hence, the smoother the field 
size, the better the outcome. This was observed in the current results where the dis-
agreements between measured and calculated data were smaller for PTV 6 than for  
PTV 3. The dependency of the detector’s performance on the field size can be also seen 
if the same detector is used for larger field sizes.  In Shimohigashi’s publication, [45], 
results between measured and calculated data obtained from the same detector were 
more satisfactory because the maximum square field sizes used there were 10, 15 and 
20 cm which were large enough regarding the resolution [45]. Considering the actual 
maximum field sizes (table 4), the detector generated a low passing rate for small fields 
and film measurements were considered as an alternative since film’s spatial resolution 
is considerably better. 
 
A plausible explanation of the poor results for small field sizes could be also the lin-
ear interpolation offered from the IBA software when converting the grid. During a 
clinical observation concerning open fields of various sizes, it was noticed a large dis-
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crepancy between measured and calculated dose levels when grid convertion was     
applied for very small field sizes. The doubt was on the linear interpolation of the grid 
size because without the applied interpolation, results were acceptable. Furthermore, it 
was noticed that an important factor was also the difference between the initial grid size 
and the final one; the smaller the difference, the smaller the discrepancies. Hence, inter-
polation could also explain to some extent the failures of measured dose profiles for 
small field sizes, especially when the dose level was not a smooth one. However, further 
studies in the clinic are going on to completely verify the problem. 
 
5.3.2. Angular dependency and other factors 
As it was already mentioned earlier, angular dependency is applied only for the 
MXX-MCube setup where the detector remains fixed and the gantry rotates around it 
while irradiating. It is important to consider it because detector’s sensitivity is different 
for different angles. According to Shimohigashi, [45], angular dependency is thought to 
be as a result of the perturbations happening at the interface between air and high-Z 
material and if it is not corrected, the measured dose would be underestimated with 
about 3 % [45]. Also Boggula et al. [46], concluded that angle correction factor applica-
tion for VMAT quality assurance improves the agreement by 4.3 % for gamma criteria 
of 2 %, 2 mm and even larger improvements for gamma criteria of 3 % and 3 mm. 
Hence, in the current measurements, angle correction factors were regarded as neces-
sary to be applied as well. 
 
On the other hand, angle correction factors may also be considered to have their 
own contribution for the unsatisfactory agreements between the data. When MXX is 
used before the comparison with the calculated data, angle correction factors provided 
by the manufacturer were applied to the measured data. Although these values were 
considered to work well, different publications showed that there was room for further 
improvement. For instance, in Feygelman’s work, [43], these values were modified and 
results improved by 1.6 % for the 3 %, 3 mm gamma criteria. With regard to results 
coming from the setup with the detector mounted on the gantry, angular dependency 
was null because the beam was all the time perpendicular to the detector. Theoretically, 
the disagreements for gantry mounted results were expected to be lower than in MXX-
MCube setup. However, based on the average values from the dose difference verifica-
tions, this did not seem to be the case. Two major reasons for this could be the sag be-
tween the fixation frame of the detector mounted in the gantry and secondly, the larger 
amount of non smooth areas in the calculated profiles for the gantry mounted detector 
cases. After the current measurements were completed, a sag up to 2 mm from the ma-
trix frame of the clinic was observed and that could have dominated the angular de-
pendency. Moreover, the different days those measurements were performed and poten-
tial drifts in calibration could have affected the final results [46]. However, it was no-
ticed that these calibration drifts were within 1 %. 
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Other possible factors 
 
An additional explanation for the differences between measured and calculated data, 
although in a smaller scale, was thought to be the dose distribution within the PTV. For 
example, in figure 22, the calculated profile is not as Gaussian as the measured profile. 
It seemed that if this curve would have had more regular shape, the differences would 
have been smaller. The grid resolution of AAA algorithm was improved from 2.5 mm to 
1 mm to see if dose distribution would get more uniform and consequently the calcu-
lated profile would become more Gaussian, but that was not the case. This fact hinted 
that the matrix detector was better suited for dose levels measured in flat areas and the 
measurement of the round or pointy areas were limited due to the detector’s poor resolu-
tion.  
 
Moreover, small field sizes pose a challenge to the AAA algorithm as shown in a 
study related to VMAT lung treatment. The other uncertainty coming from the use of 
small field sizes is related to the radiation dosimetry [47]. It has been proven that small 
fields are challenging to the dosimetry because they cause unstable conditions due to the 
secondary electron track lengths and the detector size which is comparable to the field 
size [48]. The combination (or not) of these uncertainties can be added to the uncertain-
ties list responsible for the disagreements in the high dose regions of calculated and 
measured profiles. 
5.3.3. Future work 
To minimize the errors coming from the mentioned sources, one could consider some 
future studies. At the moment, the department is working on the beam modeling modifi-
cations in order to improve the calculation accuracy, especially for small fields. Based 
on some studies done in another clinic with regard to the use of IMRT technique for 
SBRT treatments, it was noticed that the gap between measured and calculated results 
was smaller for leaf transmission factor of 1.6 instead of 1.0 which was used in the cur-
rent work. Hence, significant improvements are expected on fine tuning of the beam 
model. In addition, beam data configuration was rechecked. According to Eclipse re-
sults coming from the comparison of calculated and measured data performed in water, 
there were no discrepancies found in the high dose region. 
 
With regard to low spatial resolution of the matrix, Poppe [34.], proposed a tech-
nique which may improve the matrix performance. Even though it was applied on a 
PTW 2D array (type 10017; PTW-Freiburg, Germany) with even lower resolution than 
the MatriXX
Evolution
 the idea is worth exploring. This technique was based on a convolu-
tion correction technique which includes the response function of each detector. In brief, 
the calculated dose was convolved with the response function of an individual chamber 
of the matrix. Then the comparison between the obtained outcome and the measured 
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array signals was made. According to the author, this method would avoid most of the 
errors coming from the limited resolution of the matrix. [34.]  
 
A similar study on a MatriXX detector was made and satisfactory improvements 
were achieved. To compare the measured and calculated data, the calculated data were 
corrected by its convolution with the determined response function. Equation 12 is used 
for data correction in one direction, where M(x0) is the signal of the matrix at point x0, 
f(xi) is the calculated signal and g(x0- xi) is the response function for discrete measure-
ment points.  
 
      
               
 
   
         
 
   
    (12) 
 
For the 2D correction, a rotation-symmetric response function was created and the 
separation of the individual ion chambers was ignored. Moreover, the resolution of cal-
culated dose distribution was 0.076 cm compared to the measuring grid of 0.76 cm. The 
outcome generated by the convolution was a 32x32 matrix of single dose values, which 
were compared with the measured values. The disadvantages of such technique for the 
current results in the thesis were: the correction process did not apply for angular de-
pendent dose deliveries such as VMAT because it was designed for IMRT at 0 degree 
angle and secondly, existing OmniPro I’mRT software did not support the comparison 
of such corrected data with the measured ones. Nonetheless, more investigations for 
modifying the correction formula for VMAT data would help to minimize the low ma-
trix resolution effect on the resulted dissimilarities. [49.] In addition, other dosimetric 
characteristics of the existing matrix detector, such as its stability, dose linearity, dose 
rate response and energy dependence need to be verified particularly for FFF beams 
[45]. Knowing more about these aspects would help to better understand the behavior of 
the detector in similar situations as in the current one.  
 
With regard to the angular correction factors, Boggula et al. [46], investigated the 
feasibility of matrix detector for VMAT plans for similar geometries: with MCube 
phantom and mounted on the gantry. The author compared results between single     
correction factors used for each ionization chamber of the matrix with developed correc-
tion factors for every single ion chamber. The study managed to develop these individ-
ual correction factors and noticed significant improvements. [46.] Although it has cre-
ated the correction factors with different software, algorithms and equipments compared 
to the ones used in this thesis, the idea is an interesting one. Although it may require 
long time it can be considered as a future work for the department because results pre-
sented in the publication seemed promising, especially for small field sizes.  
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Another approach would be comparing the measurements with other the matrix de-
tector. One example can be the PiXel-segmented ionization chamber (PXC) which has 
similar features as MXX, 1024 ionization chambers arranged in a 32x32 grid. The di-
ameter of each chamber is 0.4 cm and height 0.55 cm with a distance 0.75 cm from each 
other and sensitive volume of 0.7 cm
3
. According to Stasi et al. [49], the detector per-
forms quite well for IMRT plans judging from the outcomes of the output factors, 
gamma analysis and other evaluation methods [50]. Although it is tested for IMRT only, 
it would be a good alternative to test it for VMAT as well. Finally, the absolute do-
simetry equipments can be also used to measure the smooth calculated dose. 
 
To eliminate every possible error source, the main components of VMAT delivery 
need to be checked. These main components are the dose rate, gantry speed and dynam-
ic MLCs [51]. Verification of the accuracy of these parameters and especially their 
combination needs to be done. For instance, the dynamic-MLC behavior and the rota-
tional functionality need to be verified individually and in combination. Moreover, the 
interleaf leakage needs a double check. It influences the dose delivery inaccuracy with 
the same magnitude as itself. [43.]  
 
5.4. Dosimetric verifications with film measurements 
Results from the radiochromic films were partially satisfactory. The shape of measured 
profile was in very good agreement with the calculated one. This was considered as an 
important result because this was the major problem in matrix detector’s results. Conse-
quently, it demonstrated that indeed one of the key reasons of the disagreement between 
measured and calculated data was due to the detector’s limitation and small field sizes.  
 
On the other hand, the unsatisfactory part was the large gap between calculated and 
measured doses, as can be seen from figure 37. On a positive note, this aspect was 
proven to be correct from the detector’s measurement which implied that this unsatis-
factory result in the film measurements was due to film technical issues. Thus, some 
explanations on what might have influenced such result are given next.  
 
In general, when doing radiochromic film measurements there are few uncertainty 
sources that have to be considered. According to their sources, uncertainties are classi-
fied into two main groups: inaccuracies from calibration process and from dose meas-
urements. Inaccuracies coming from the calibration can be from the beam delivery and 
from the calibrated film itself (for example film in-homogeneities). As for the uncertain-
ties coming from dose measurements, the imprecision could come from the calibration 
curve, irradiated film and/or post-irradiation processes (room temperature, film develop-
ing time, age of the film).[52.]  
 
 61 
 
Keeping in mind these sources, it was natural to investigate all of them regarding to 
the current measurements. The calibration process was reconsidered and was concluded 
that it was correct because the relevant recommendations (as described in section 3.5.1) 
based on approved guidelines were followed together with the medical physicists of the 
department. Regarding the post-irradiation processes, the film was stored in a dark box, 
in room temperature, for 18 hours which were considered as optimal conditions accord-
ing to Casanova et al. and Andres [35; 36]. As for the quality of the film, Casanova et 
al. and Reinhardt, [35; 53], proved that the current film was a feasible one for IMRT 
quality assurance and its overall inaccuracies would not exceed 2 %. These inaccuracies 
would be the film non-homogeneity, fit accuracy, intra-batch variations and artefacts 
generated from the scanner [34; 52]. Moreover, new measurements with new films and 
new calibration curves were performed and again the difference between the data sets 
was significant and unacceptable. Therefore, keeping in mind that the mentioned inac-
curacies would sum up only for about 2 %, there is still a large percentage of inaccuracy 
that cannot be explained, yet.  
5.4.1. Future work 
Some future work that can be done for improving the inaccuracies mentioned earlier is 
by investigating if there is any correlation between the results of the film and the ones 
from the MXX-MCube. It was an interesting fact that for the same plan, PTV 3 and 
dose/fraction of 4 Gy, the film and the MXX-MCube measurements had similar dis-
agreements ranging from 8-10 %, in the Y-direction. If such correlation exists, this 
could hint that there may be an uncertainty with either the beam delivery or with the 
TPS calculations; the last one being most likely the issue.  
 
Another aspect to be considered is to use film dosimetry starting with the simplest 
plans and dose distributions that need no complex beam modulation, for example open 
fields. If the results are successful, then it can be preceded with more complex plans. 
This would ensure that film quality, film calibration and dose delivery are correct.  
 
To minimize any possible erroneousness regarding the film, one could also work on 
the calibration curve by developing or using a more complex equation that generates 
such curve. However, one must be careful with this modification because the more 
complex the equation, the more parameters involved, thus uncertainty increases [52].  
Furthermore, another relatively important flaw of the film that could influence the re-
sults for absolute dosimetry is the heterogeneity within the same film and inter-batch 
variations, due to the manufacturing process. One could avoid the inter batch variations 
by using films from the same batch only and the same scanning device which was the 
case in this study. Finally, as for the heterogeneity, one could tackle it by scanning mul-
tiple films and taking their average as the measured data [8].  
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6. CONCLUSION 
In this thesis, the aim was clinical commissioning of flattening filter free (FFF) 6 MV 
photon beam for stereotactic body radiation therapy (SBRT) volume modulated arc 
therapy (VMAT) lung treatment. This was done by creating two different spherical tar-
get volumes with diameters 3 cm (PTV 3) and 6 cm (PTV 6) and four radiotherapy 
plans with different prescribed doses. Dose distribution within the PTVs was planned 
according to RTOG protocol. Then the treatment plans were transferred to cubic solid 
water phantom. Two techniques were used to assess the difference between measured 
and calculated dose distributions: 2D ionization chamber matrix detector and radio-
chromic film. 
 
Results obtained from the matrix detector were partially satisfactory because the 
dose level of measured and calculated dose profiles were in good agreement for PTV 6 
only. The average disagreement was in every plan of PTV 6 within the accuracy crite-
rion suggested by technical reports series (TRS) 398. Based on the same evaluation pro-
tocol, PTV 3 was not acceptable. Furthermore, the disagreement was smaller when the 
matrix was on the treatment couch than when it was placed on gantry holder. This is 
most likely because of the sag between the fixation frame and the detector. Going in 
more details, in every measurement the highest disagreements were in the regions where 
the calculated profile had rapid dose level changes. The failure of the detector to cor-
rectly measure these areas was thought to be mainly due to its low spatial resolution 
combined with small field sizes and the challenge that small field sizes introduce to the 
dose calculation algorithm. There were also deviations in overall dose levels. Future 
studies related to these problems are required and the department is currently working 
on to fine tune the beam modelling used for the dose calculation of small fields.  
 
Results from the film measurements showed that the measured dose profile matched 
almost perfectly with the calculated profile. It was a crucial outcome considering that 
this was the main problem in the detector measurements. The only reason making the 
film measurement partly successful was the large gap in dose levels between measured 
and calculated dose profiles. That did not exist with the matrix detector. Consequently, 
this gap seen on film measurement was thought to be mainly due to the inaccuracies 
coming either from film calibration process or post-irradiation film process. Further 
studies on these issues are also necessary and the department has already started them.  
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As a final remark, based on the results obtained with the matrix detector and radio-
chromic film, the commissioning of the 6 MV FFF beam for SBRT lung treatment is 
considered as partly successful. This means that the shape of the dose distributions can 
be accurately calculated but there exist unacceptable dose level deviations for very 
small target volumes. Before FFF 6 MV beams are clinically used, studies concerning 
the main problems mentioned earlier are needed and additional measurements for dif-
ferent modulated beams are required. 
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